

For personal use only

**Rhinomed Limited**

ABN 12 107 903 159

**Audited financial report  
for the year ended 30 June 2017**

**Rhinomed Limited** ABN 12 107 903 159  
**Audited financial report - 30 June 2017**

**Contents**

	Page
Corporate directory	1
Directors' report	2
Auditor's Independence Declaration	23
Corporate governance statement	24
Financial statements	
Consolidated statement of profit or loss and other comprehensive income	25
Consolidated statement of financial position	26
Consolidated statement of changes in equity	27
Consolidated statement of cash flows	28
Note to the consolidated financial statements	29
Directors' declaration	64
Independent auditor's report to the members	65

For personal use only

**Rhinomed Limited  
Corporate directory**

<b>Directors</b>	Mr Michael Johnson <i>Chief Executive Officer and Executive Director</i>  Dr Eric Knight <i>Non-Executive Director</i>  Mr Ron Dewhurst <i>Non-Executive Chairman</i>  Mr Brent Scrimshaw <i>Non-Executive Director</i>
<b>Secretary</b>	Mr Phillip Hains  Mr Justyn Stedwell
<b>Principal registered office in Australia</b>	97 Green Street Cremorne Victoria 3121 Australia +61 (0)3 8416 0900
<b>Share and debenture register</b>	Automic Registry Services PO Box 223 West Perth Western Australia 6953 +61 (0) 8 9321 2337
<b>Auditor</b>	HLB Mann Judd Level 9, 575 Bourke Street Melbourne Victoria 3000
<b>Bankers</b>	National Australia Bank (NAB) 330 Collins Street Melbourne Victoria 3000
<b>Stock exchange listings</b>	Australian Securities Exchange: - Ordinary Fully Paid Shares (Code: RNO)
<b>Website</b>	<a href="http://www.rhinomed.global">www.rhinomed.global</a>

For personal use only

# Rhinomed Limited

## Directors' report

### 30 June 2017

The Directors present their report, together with the financial statements, of the consolidated entity (referred to hereafter as the 'consolidated entity' or 'Group') consisting of Rhinomed Limited (referred to hereafter as the 'Company' or 'parent entity') and the entities it controlled for the year ended and as at 30 June 2017.

## Directors

The following persons were Directors of Rhinomed Limited during the whole of the financial year and up to the date of this report, unless otherwise stated:

Mr Michael Johnson  
Dr Eric Knight  
Mr Ron Dewhurst  
Mr Brent Scrimshaw

## Principal activities

The Group's principal activities in the course of the financial year were research, development and commercialisation of consumer and medical devices. There were no significant changes in the nature of the Group's principal activities during the financial year.

## Dividends

No dividends were paid or proposed during the year (2016: nil).

## Operating and financial review

### Results

Total receipts for the financial year were \$2.02 million, up 139 percent from \$0.85 million in from 2016. Revenue from continuing operations for the financial year increased 70 percent to \$1.7 million up from \$1.0 million in 2016.

The Group reported a loss of \$4.5 million for the financial year, down 26 percent from \$6.0 million in 2016. Net cash used in operating expenses more than halved (down 51 percent) to \$3.0 million. Operating expenses have tightened, as the Company focused on streamlining and building its global distribution presence and leveraging key relationships with key retailers.

This solid progress reflects the significant efforts made over the course of the financial year opening distribution channels, principally in the North American and Australian markets. Into this growing base of stores the Company shipped close to 150,000 product units throughout the financial year.

Over the course of the current financial year the Company set several key milestones:

- Increase distribution amongst our existing key accounts in our three core markets;
- Increase the overall retail footprint through strategic focus on high value retail/pharmacy networks;
- Expand awareness of Mute amongst clinical channels to begin establishing referrals.

Pleasingly, the Company has made significant progress in achieving each of these milestones.

### Key products

Turbine and Mute are individually customisable nasal dilators that enhance nasal breathing and reduce congestion without placing pressure on the septum.

Mute is designed to increase airflow and reduce snoring, thereby supporting sleep quality. Mute is light and flexible and can be worn comfortably during sleep. An independent in-home User Trial, peer-reviewed literature reviews and market research in the US, UK and Australia has assisted in developing an understanding of the scope of the global market opportunity for breathing technologies.

**Rhinomed Limited**  
**Directors' report**  
**30 June 2017**  
(continued)

## **Operating and financial review (continued)**

### **Key products (continued)**

Turbine is designed to make breathing easier during aerobic exercise and activity. Because retention in the nose during these activities is vital, Turbine employs more robust materials and retention features on the paddles and curved arms to hold the device in place during intense exercise.

### **Regulatory status**

The Company launched Turbine in 2014. Mute was launched initially online in December 2014, then into the Australian retail market in late March 2015.

Mute and Turbine are registered with regulatory authorities in several key markets in Australia with the TGA, in the USA with the FDA, in Europe where it has received a CE Mark and in Canada with Canada Health. During the course of the year the Company sought to expand and subsequently achieved regulatory approval in Taiwan with the Taiwanese FDA.

The Company's products are now sold over-the-counter and online through pharmacies, sleep clinics and sports stores.

### **Distribution**

Over the course of this financial year the Company was able to build relationships with several important wholesalers in both the USA and Australia. These included AmerisourceBergen Corporation, McKesson, Vittoria Industries, Sigma Healthcare, Symbion and The Linde Group (BOC Limited).

These wholesalers play an important role in expanding our retail footprint and provide access to a significant retail footprint. During the current financial year, the Company stocked approximately 3,600 stores and opened up access to an additional 4,000<sup>1</sup> stores during Q4 of 2017.

Post 30 June the Company subsequently announced an increase in its Walgreens store count from 891<sup>1</sup> to 4,300<sup>1</sup> stores and that the Hamacher Resource Group has included Mute in its Planogram, which is utilised by some 10,000 independent pharmacies throughout the USA.

<sup>1</sup> Stores numbers are estimated at the date of this report.

### **Operations**

In line with the Company's strategy, Mute continues to be a major area of growth for the Company. Mute contributed the majority of sales. Nasal congestion, snoring and poor sleep continue to emerge as major contributors of poor health outcomes and chronic disease. The Company continues to believe that the unmet clinical need for an over-the-counter, no-drug, low cost, low invasive, well tolerated solution is compelling.

Turbine's role as a core brand that socialises and raises awareness of nasal breathing remains critical. In July 2017, Chris Froome - one of the Company's key ambassadors - won his fourth Tour de France. He continues to use the Turbine as a part of this kit and Turbine continues to be worn by key sporting personalities, globally.

The Company continues to deliver strong gross margins and has maintained these throughout the sell-in process with major retailers. Sales and marketing costs for the financial year have been high reflecting the cost of promotional campaigns to support new retail accounts and growth in brand awareness in these markets. This investment has been important in ensuring the Company meets store sell-through expectations in these markets. The Company has leveraged growing awareness and endorsement amongst sleep and dental professionals and intends to continue to build this as it focuses on store presence, merchandising and PR opportunities.

Mute has featured in a significant number of US, UK and Australian media stories during the year: including Live with Kelly, Sirius Radio, ABC, NBC TV, Channel 7 National News and Marie Claire. Many of these media opportunities have involved key opinion leaders in the sleep and respiratory fields.

## **Operating and financial review (continued)**

### **Operations (continued)**

Staff numbers remained stable over the course of the year. The Company will continue to monitor corporate and overhead costs to ensure timely investment and appropriate levels of expenditure.

### **Corporate**

During the year, the Company undertook several capital management initiatives in anticipation of its planned growth. In January 2017, it secured a \$2.0 million working capital facility. This facility was not utilised during the current financial year. In March 2017, the Company raised \$2.1 million with two key US based shareholders and subsequently welcomed Mr Whitney George as its cornerstone investor, with 17 percent of the Company's equity.

In addition, at a Shareholders general meeting held in March 2017, shareholders voted to consolidate the Company's stock on a one share for every ten shares held basis. Shareholders also voted to alter the constitution to allow for the sale of unmarketable parcels.

The consolidation was subsequently completed on 11 May and in July 2017, a letter regarding the unmarketable parcels was despatched to shareholders. The sale of unmarketable parcels is slated to take place in late August. Both these initiatives are designed to ensure shareholders are able to optimise their holdings in Rhinomed, ensure the Company manages prudently its administrative costs and position the business to best capture the considerable progress that has been made to date.

The Company received research and development tax rebates of \$280,000 compared with \$437,000 in the previous financial year. This decrease reflects the Company's increasing focus on expanding the distribution footprint for its lead products.

### **R&D**

As a result of the Company's focus on commercialisation, R&D expenditure was significantly down for the year. Amount of costs incurred in the current year has been \$65,000 compared to the \$234,000 incurred in 2016.

Interest in the Company's technologies from the sleep medicine community continues to grow at a rapid rate. Rhinomed exhibited at both the American Sleep Medicine conference and the American Dental Sleep Medicine conference in June and both strongly illustrated the growing recognition of the importance of the nose and nasal airflow and its positive impact on both efficacy and compliance with a range of other sleep therapies, including CPAP and oral devices. Rhinomed continues to build a reputation and be recognised as an innovator and global leader in improving nasal airflow, breathing and sleep.

### **Events after the reporting date**

On 19 July 2017, the Company announced that it had received purchase orders confirming US Pharmacy giant Walgreens had placed Rhinomed's four SKU product range (Trial, Small, Medium and Large pack) of the Mute sleep and breathing technology product in approximately 4,300 pharmacy/drugstores across the USA. In addition, the Hamacher Resource Group confirmed that two of the Mute range (Trial and Medium) would be included in their planogram. This planogram is utilised by some 10,000 independent pharmacy/drugstores throughout the USA.

**Rhinomed Limited**  
**Directors' report**  
**30 June 2017**  
(continued)

## **Operating and financial review (continued)**

### **Events after the reporting date (continued)**

On 16 August 2017, the following dormant fully owned subsidiaries within the Group have been de-registered:

- Helicon (Asia) Pty Ltd
- Helicon (China) Pty Ltd
- Helicon (Korea) Pty Ltd
- Helicon International Pty Ltd (Formerly Helicon International Limited)
- Leading Edge Instruments Pty Ltd (Formerly Leading Edge Instruments Limited)
- Vibrovein Pty Ltd

Refer to note 18 for further details on the group structure within the Group.

No other matter or circumstance has arisen since 30 June 2017 that has significantly affected, or may significantly affect the Group's operations, the results of those operations, or the Group's state of affairs in future financial years.

### **Financial position**

The Group held cash reserves of \$1,666,883 at 30 June 2017, a decrease of \$945,874 from the previous period end. The Group's net assets were \$5,332,093 compared with \$7,115,370 for the previous year. The net carrying value of the Group's intangible assets of \$3,678,251 compared with \$4,039,879 for the previous year.

### **Business strategy and future prospects**

The Company expects continued strong performance in the new financial year as it extends the reach of Mute into retail pharmacies and sleep clinics in key initial markets: USA, Canada, the United Kingdom and Australia. The Company has recognised the need to focus sales and marketing activities in order to leverage these opportunities and will curtail some Turbine marketing activities.

There is strong interest in the Company's technologies and their role in opening conversations and developing relationships with consumers about sleep quality. This interest opens opportunities for strategic relationships which will assist the Company expand its footprint.

### **Significant changes in state of affairs**

Other than that has been disclosed, there were no significant changes in the state of affairs of the Group during the current period.

### **Material business risks**

The Company is subject to normal business risks, including but not limited to interest rate movements, labour conditions, government policies, securities market conditions, exchange rate fluctuations, and a range of other factors which are outside the control of the Board and Management.

More specific material risks of the biotechnology sector and the Company include, but are not limited to:

- Scientific, technical and clinical - product development requires a high level of scientific rigour, for which the outcomes cannot be known beforehand. Activities are experimental in nature so the risk of failure or delay is material. Key development activities, including clinical trials and product manufacture, are undertaken by specialist contract organisations; and there are risks in managing the quality and timelines of these activities.
- Regulatory - products and their testing, may not be approved by, or be delayed by regulatory bodies whose approvals are necessary before products can be sold in market.
- Financial - the Group currently, and since inception, does not receive sufficient income to cover operating expenses. There is no certainty that additional capital funding may not be required in the future, and no assurance can be given that such funding will be available, if required.

## **Operating and financial review (continued)**

### **Material business risks (continued)**

- Intellectual property (IP) - commercial success requires the ability to develop, obtain and maintain commercially valuable patents, trade secrets and confidential information. Gaining and maintaining the IP across multiple countries; and preventing the infringement of the Group's exclusive rights involves management of complex legal, scientific and factual issues. The Company must also operate without infringing upon the IP of others.
- Commercialisation - the Group relies, and intends to rely, upon corporate partners to market, and in some cases finalise development of its products, on its behalf. There are risks in establishing and maintaining these relationships, and with the manner in which partners execute on these collaborative agreements.
- Product acceptance and competitiveness - a developed product may not be considered by key opinion leaders or the end customer to be an effective alternative to products already on market, or new superior future products may be preferred.
- Product liability - a claim or product recall would significantly impact the Company. Insurance, at an acceptable cost, may not be available or be adequate to cover liability claims if a marketed product is found to be unsafe.
- Key personnel - the Group's success and achievements against timelines depend on key members of its highly qualified, specialised and experienced management and scientific teams. The ability to retain and attract such personnel is important.

In accordance with good business practice the Group's management actively and routinely employs a variety of risk management strategies. These are broadly described in the Corporate Governance Statement.



**Rhinomed Limited**  
**Directors' report**  
**30 June 2017**  
(continued)

**Information on directors**

The names of Directors in office at any time during or since the end of the year are:

<b>Mr Michael Johnson</b> <i>Chief Executive Director and Executive Director</i>		
Experience and expertise	Mr Johnson is also a director of Melbourne based Cogentum, one of Australia's leading market oriented strategic advisory firms based in Melbourne, Australia. Over the last 20 years Mr Johnson has worked in and for a wide spectrum of companies from ASX300 through to start-up companies in Life Sciences, Cleantech, Financial Services, Energy and Utilities, Manufacturing, Marketing and Communication, Automotive, and Consumer packaged goods. His most recent work has focused on helping companies envision and create new growth and innovation, manage and grow technology platforms and achieve sustainable growth through business model innovation. Mr Johnson has been a Principal at two leading global consulting firms where he advised on innovation and competing in heavily regulated industries. Before that he held roles within some of the world's most successful marketing and communication firms. Where he launched a number of high profile new products and brands. Mr Johnson has received a Master's degree in Entrepreneurship and Innovation from Swinburne University and a Bachelor's degree with distinction in business from Monash University.	
Date of appointment	1 February 2013	
Committees	Member of the Remuneration and the Audit Committee	
Other listed company directorships in the past 3 years	-	
Interests in shares and options	Fully paid ordinary shares	174,553
	Options	4,000,000

<b>Mr Ron Dewhurst</b> <i>Non-Executive Chairman</i>		
Experience and expertise	Mr Dewhurst has spent 40 years in the Investment Banking and Asset Management Industries, covering Australia, Asia, Europe and America. In 1992 he joined J P Morgan where he ran the Asian and European equities divisions in Hong Kong and London before being appointed Head of Americas for J P Morgan Asset Management. In 2004 he was CEO of IOOF Holdings Ltd and from 2008 until 2013 he was Senior Executive Vice President and Head of Global Investment Managers for Legg Mason Inc based in the U.S.A. Previously, Mr Dewhurst worked within Melbourne-based broking firm McCaughan Dyson going on to become CEO of what became ANZ McCaughan Ltd.	
Date of appointment	1 December 2015	
Committees	Member of the Remuneration and the Audit Committee	
Other listed company directorships in the past 3 years	Diversa Ltd (ASX: DVA) OneVue Holdings Ltd (ASX: OVH) Sprott Inc. (TSX: SII)	
Interests in shares and options	Fully paid ordinary shares	7,184,680
	Options	1,000,000

For personal use only

**Rhinomed Limited**  
**Directors' report**  
**30 June 2017**  
(continued)

**Information on directors (continued)**

<b>Dr Eric Knight</b> <i>Non-Executive Director</i>		
Experience and expertise	Dr Knight brings a depth of experience in corporate strategy and management, having previously worked for the Boston Consulting Group. He specialises in strategy implementation and corporate innovation in the healthcare, digital media, and financial services sectors. Dr Knight draws upon his expertise to support the organisation's internationalisation and commercialisation strategy. Dr Knight is a Graduate of the Australian Institute of Company Directors, and is based at the University of Sydney Business School, where he leads strategy and entrepreneurship teaching in the MBA.	
Date of appointment	12 February 2014	
Committees	Chair of the Audit Committee and Member of the Remuneration Committee	
Other listed company directorships in the past 3 years	-	
Interests in shares and options	Fully paid ordinary shares	76,158
	Options	1,000,000

<b>Mr Brent Scrimshaw</b> <i>Non-Executive Director</i>		
Experience and expertise	Mr Scrimshaw brings a unique understanding of the requirements of building disruptive brands and businesses worldwide. During a 19-year career with Nike Inc. where he became Vice President and Chief Executive of Western Europe and a member of the global corporate leadership team, he was responsible of many of Nike's major growth and brand strategies. He is also a non-executive director of Fox Head Inc, one of the world's leading Motocross and Action Sports brands in California, USA.	
Date of appointment	12 February 2014	
Committees	Chair of the Remuneration Committee	
Other listed company directorships in the past 3 years	Catapult Sports Ltd (ASX: CAT)	
Interests in shares and options	Fully paid ordinary shares	75,918
	Options	1,000,000

For personal use only

**Rhinomed Limited**  
**Directors' report**  
**30 June 2017**  
(continued)

**Information on key management personnel**

The names of key management personnel in office at any time during or since the end of the year are:

<b>Ms Justine Heath</b> <i>Chief Financial Officer and Chief Operating Officer</i>		
Experience and expertise	Ms Heath is a Fellow of the Institute of Chartered Accountants, Australia and has more than two decades experience in senior finance and operational roles. Ms Heath brings considerable executive experience in healthcare and technology development companies and a strong commercial background. She started her career at PWC before working at Santos and then in senior roles at healthcare major Faulding and as COO/CFO at ASX listed Hexima before its privatisation. More recently Ms Heath was CFO at hearing aid company Blamey Saunders.	
Date of appointment	6 February 2015	
Date of resignation	24 October 2016	
Interests in shares and options	Fully paid ordinary shares	Nil
	Options	500,000

<b>Mr Shane Duncan</b> <i>Vice President Global Sales and Marketing</i>		
Experience and expertise	Mr Duncan has over 20 years International experience across pharmaceutical marketing, sales and medical communications. Mr Duncan was formerly the Founder and Managing Director of Lifeblood which is an Australian based medical education and healthcare advertising agency.	
Date of appointment	23 August 2015	
Interests in shares and options	Fully paid ordinary shares	30,000
	Options	500,000

<b>Mr Phillip Hains</b> <i>Joint Company Secretary</i>		
Experience and expertise	Mr Hains is a Chartered Accountant operating a specialist public practice, 'The CFO Solution'. The CFO Solution focuses on providing back office support, financial reporting and compliance systems for listed public companies. A specialist in the public company environment, Mr Hains has served the needs of a number of company boards and their related committees. He has over 20 years' experience in providing businesses with accounting, administration, compliance and general management services. He holds a Master of Business Administration from RMIT and a Public Practice Certificate from the Institute of Chartered Accountants.	
Date of appointment	24 December 2012	
Interests in shares and options	Fully paid ordinary shares	1,273,358
	Options	Nil

For personal use only

**Rhinomed Limited**  
**Directors' report**  
**30 June 2017**  
(continued)

**Information on key management personnel (continued)**

<b>Mr Justyn Stedwell</b> <i>Joint Company Secretary</i>		
Experience and expertise	Mr Stedwell is a professional Company Secretary with over 8 years' experience as a Company Secretary in ASX listed companies within various industries including IT & Telecommunications, Biotechnology, and Mining. He has completed a Bachelor of Business & Commerce (Management & Economics) at Monash University, a Graduate Diploma of Accounting at Deakin University, a Graduate Diploma in Applied Corporate Governance with Chartered Secretaries Australia and Graduate Certificate of Applied Finance with Kaplan Professional.	
Date of appointment	22 June 2011	
Interests in shares and options	Fully paid ordinary shares	Nil
	Options	Nil

**Meetings of directors**

The number of meetings of the Company's Board of Directors ('the Board') and of each board committee held during the year ended 30 June 2017, and the numbers of meetings attended by each Director were:

	<b>Full board</b>		<b>Audit committee</b>		<b>Remuneration committee</b>	
	<b>Attended</b>	<b>Held</b>	<b>Attended</b>	<b>Held</b>	<b>Attended</b>	<b>Held</b>
Michael Johnson	13	13	8	8	5	5
Eric Knight	13	13	8	8	5	5
Ron Dewhurst	13	13	7	8	5	5
Brent Scrimshaw	12	13	-	-	4	5

Held: represents the number of meetings held during the time the Director held office or was a member of the relevant committee.

**Remuneration report**

The remuneration report, which has been audited, outlines the key management personnel remuneration arrangements for the consolidated entity, in accordance with the requirements of the *Corporations Act 2001* and its Regulations.

The remuneration report is set out under the following main headings:

- (a) Principles used to determine the nature and amount of remuneration
- (b) Details of remuneration
- (c) Service agreements
- (d) Share-based compensation
- (e) Relationship between remuneration policy and group performance
- (f) Key management personnel disclosures

**(a) Principles used to determine the nature and amount of remuneration**

*Principles of compensation*

The Board's policies for determining the amount and nature of compensation of key management personnel of the Group are as follows:

For personal use only

## **Remuneration report (continued)**

### **(a) Principles used to determine the nature and amount of remuneration (continued)**

#### *Principles of compensation (continued)*

The compensation structure for key management personnel is based on a number of factors, including length of service, specific experience of the individual, the individual's performance and contribution to the Group and the overall performance of the Group.

The compensation structure of individual key management personnel is embodied in individual service contracts that include incentives designed to reward key management personnel for results achieved and to retain their services, as well as to create goals congruence between directors, executives and shareholders.

The Board's policy for determining remuneration is based on the following:

- (i) The policy is developed by and approved by the board;
- (ii) All Key Management Personnel ("KMP") receive a base remuneration;
- (iii) Performance incentives are generally only paid once predetermined key performance indicators (KPI's) have been met; and
- (iv) Incentives paid in the form of options are designed to align the interests of the Director and Company with those of shareholders.

All remuneration paid to KMP is valued at the cost to the Group and expensed. KMP are also entitled and encouraged to participate in the employee share and option arrangements to align directors' interest with shareholders.

#### *Fixed remuneration*

Fixed compensation consisted of a base salary (calculated on a total cost basis, including any fringe benefits tax related to employee benefits) as well as employer contributions to superannuation funds.

Compensation levels are reviewed annually by the Remuneration Committee through a process that considers individual and the Group's achievement.

#### *Performance linked remuneration*

Performance linked compensation includes short term incentives (STI), in the form of cash bonuses paid only upon the achievement of predetermined KPIs.

Long term incentives (LTI) provided are options over ordinary shares in the Group.

Performance remuneration is designed to align the targets of the business units with the targets of those executives in charge of meeting those targets. Incentive based payments may be granted to executives based on specific annual targets and KPI being achieved. KPI's include financial and/or operational performance targets. In addition, equity payments in the form of share options may be issued to KMP to further align their interests with the performance of the Group.

#### *Short term incentive Bonus (STI)*

No STI bonuses were granted to KMP during the financial year ended 30 June 2017.

#### *Long term incentives (LTI)*

Options granted to KMP during the financial year ended 30 June 2017 are shown in item (d) of this remuneration report. They vested on granting.

**Rhinomed Limited**  
**Directors' report**  
**30 June 2017**  
(continued)

**Remuneration report (continued)**

**(a) Principles used to determine the nature and amount of remuneration (continued)**

*Relationship between the remuneration policy and the group's performance*

The remuneration of executives consists of an unrisksed element (base pay) and cash bonuses based on performance in relation to key strategic, non-financial measures linked to drivers of performance in future reporting periods. As such, remuneration is not linked to the financial performance of the Group in the current or previous reporting periods.

**(b) Details of remuneration**

**Amounts of remuneration**

The key management personnel of the consolidated entity consisted of the following directors of Rhinomed Limited:

- Michael Johnson - Executive Director
- Ron Dewhurst - Non-Executive Chairman
- Brent Scrimshaw - Non-Executive Director
- Eric Knight - Non-Executive Director

And the following persons:

- Justine Heath - Chief Financial Officer and Chief Operating Officer (resigned on 24 October 2016)
- Shane Duncan - Vice President Global Sales and Marketing

Details of the remuneration of the key management personnel of the consolidated entity are set out in the following tables.

2017	Short-term employee benefits		Post-employment benefits	Long-term benefits	Share based payments	Total	Proportion of remuneration performance related
	Cash salary and fees	Cash bonus	Non-monetary benefits	Super-annuation	Long service leave		
	\$	\$	\$	\$	\$	\$	
<b>Non-executive Directors</b>							
Ron Dewhurst	76,712	-	-	7,283	-	83,995	0%
Brent Scrimshaw	54,794	-	-	5,205	-	165,499	64%
Eric Knight	54,794	-	-	5,205	-	165,499	64%
<b>Executive Directors</b>							
Michael Johnson	230,692	-	-	19,308	-	672,000	63%
<b>Other KMP</b>							
Justine Heath	78,067	-	-	5,910	-	83,977	0%
Shane Duncan	221,591	-	-	-	-	221,591	0%
<b>Total KMP compensation</b>	<b>716,650</b>	<b>-</b>	<b>-</b>	<b>42,911</b>	<b>-</b>	<b>1,392,561</b>	

**Rhinomed Limited**  
**Directors' report**  
**30 June 2017**  
(continued)

**Remuneration report (continued)**

**(b) Details of remuneration (continued)**

**Amounts of remuneration (continued)**

2016	Short-term employee benefits		Post-employment benefits	Long-term benefits	Share based payments	Total	Proportion of remuneration performance related
	Cash salary and fees	Cash bonus	Non-monetary benefits	Super-annuation	Long service leave		
	\$	\$	\$	\$	\$	\$	
<b>Non-executive Directors</b>							
Martin Rogers	35,000	-	-	-	-	35,000	0%
Ron Dewhurst	44,749	-	-	4,251	-	107,000	0%
Brent Scrimshaw	54,795	-	-	5,205	-	60,000	0%
Eric Knight	54,795	-	-	5,205	-	60,000	0%
<b>Executive Directors</b>							
Michael Johnson	230,692	-	-	19,308	-	250,000	0%
<b>Other KMP</b>							
Justine Heath	200,913	-	-	19,087	-	250,000	18%
Shane Duncan	229,295	-	-	-	-	259,295	17%
<b>Total KMP compensation</b>	<b>850,239</b>	<b>-</b>	<b>-</b>	<b>53,056</b>	<b>-</b>	<b>1,021,295</b>	

**(c) Service agreements**

*Executives*

Remuneration and other terms of employment for key management personnel are formalised in service agreements. Details of these agreements are as follows:

**Name:** Michael Johnson

**Title:** Executive Director appointed 1 February 2013

**Term of Agreement:** Standard rolling agreement (no fixed term)

**Details:** The employment conditions of Michael Johnson are formalised in an employment contract. This contract includes a termination period of three months. As a KMP, Mr Johnson is entitled to participate in the Group's employee share option plans.

**Name:** Justine Heath

**Title:** Chief Financial Officer and Chief Operating Officer appointed 6 February 2014, resigned 24 October 2016

**Term of Agreement:** Standard rolling agreement (no fixed term)

**Details:** The employment conditions of Justine Heath were formalised in a contract of employment at the time of appointment. This contract includes a termination period of nine months. As a KMP, Ms Heath is entitled to participate in the Group's employee share option plans.

**Name:** Shane Duncan

**Title:** Vice President Global Sales and Marketing appointed 23 August 2015

**Term of Agreement:** Standard rolling agreement (no fixed term)

For personal use only

**Rhinomed Limited**  
**Directors' report**  
**30 June 2017**  
(continued)

**Remuneration report (continued)**

**(c) Service agreements (continued)**

*Executives (continued)*

**Details:** The employment conditions of Shane Duncan were formalised in a contract of employment at the time of appointment. This contract does not include an additional termination period other than what is required by law. As a KMP, Mr Duncan is entitled to participate in the Group's employee share option plans.

*Non-executive Directors*

In accordance with best practice corporate governance, the structure of non-executive directors and executive remunerations is separate and distinct.

Fees and payments to non-executive directors reflect the demands which are made on, and the responsibilities of, the Directors. Non-executive directors' fees and payments are reviewed annually by the Board of Directors. The Board of Directors considers advice from external sources as well as the fees paid to non-executive directors of comparable companies when undertaking the annual review process. Each director receives a fee for being a director of the Company.

The Chairman's fees are determined independently to the fees of other non-executive directors based on comparative roles in the external market. The chairman is not present at any discussions relating to determination of his own remuneration.

Directors' fees cover all main board activities and committee memberships.

All non-executive directors have an agreement for services with the Company that is ongoing. There is no termination clause within the agreement and no entitlement to a termination payment.

Key management personnel have no entitlement to termination payments in the event of removal for misconduct.

**(d) Share-based compensation**

*Issue of shares*

There has been no share based payments for the period ended 30 June 2017.

*Options*

The number of options over ordinary shares granted to and vested by directors and other key management personnel as part of compensation during the year ended 30 June 2017 are set out below:

Name	Number of options granted during the year		Number of options vested during the year	
	2017	2016	2017	2016
Phillip Hains	-	-	-	-
Michael Johnson	4,000,000	-	4,000,000	-
Eric Knight*	1,000,000	-	1,000,000	-
Ron Dewhurst*	-	1,000,000	-	1,000,000
Brent Scrimshaw	1,000,000	-	1,000,000	-
Justine Heath*	-	500,000	-	500,000
Shane Duncan*	-	500,000	-	500,000
	<b>6,000,000</b>	<b>2,000,000</b>	<b>6,000,000</b>	<b>2,000,000</b>

\*On 3 May 2017 the share capital of the Company has been consolidated through the conversion of every ten shares into one share. Basic and diluted loss per share for the prior financial year have been restated to align with the current year's amount.

For personal use only



**Rhinomed Limited**  
**Directors' report**  
**30 June 2017**  
(continued)

**Remuneration report (continued)**

**(d) Share-based compensation (continued)**

*Options (continued)*

The terms and conditions of each grant of options over ordinary shares affecting remuneration of directors and other key management personnel in this financial year or future reporting years are as follows:

Grant date	Vesting date and exercisable date	Expiry date	Exercise price	Fair value per option at grant date
28/04/2017	-	30/04/2020	\$0.27	\$0.1055

Options granted carry no dividend or voting rights and the value of the grant was determined in accordance with applicable Australian Accounting Standards.

There have been no alterations to the terms or conditions of any grants since grant date. All options granted entitle the holder to one ordinary share for each option exercised.

Values of options over ordinary shares granted, exercised and lapsed for directors and other key management personnel as part of compensation during the year ended 30 June 2017 are set out below:

	Value of options granted during the year <sup>1</sup>	Value of options exercised during the year	Value of options lapsed during the year	Remuneration consisting of options for the year
Michael Johnson	422,000	-	916,931	63%
Eric Knight	105,500	-	202,790	64%
Ron Dewhurst	-	-	-	-
Brent Scrimshaw	105,500	-	202,790	64%
Justine Heath <sup>2</sup>	-	-	-	-
Shane Duncan	-	-	-	-
	<b>633,000</b>	<b>-</b>	<b>1,322,511</b>	

<sup>1</sup> Options values at grant date are determined using the Black-Scholes method.

<sup>2</sup> Resigned on 24 October 2016.

**(e) Relationship between the remuneration policy and group performance**

As detailed under heading (a), remuneration of executives consists of an unrisks element (base pay) and cash bonuses based on performance in relation to key strategic, non-financial measures linked to drivers of performance in future reporting periods. As such, remuneration is not linked to the financial performance of the Group in the current or previous reporting periods.

The tables below set out summary information about the Group's earnings and movement in shareholder wealth for the five years to 30 June 2017:

	30 June 2017	30 June 2016	30 June 2015	30 June 2014	30 June 2013
	\$	\$	\$	\$	\$
Revenue	1,742,315	1,097,315	492,888	291,069	300,500
Net loss before tax	(4,832,477)	(6,435,986)	(5,887,329)	(3,922,702)	(20,226,248)
Net loss after tax	(4,441,578)	(5,998,529)	(5,316,992)	(3,534,577)	(19,559,713)

For personal use only

**Rhinomed Limited**  
**Directors' report**  
**30 June 2017**  
(continued)

**Remuneration report (continued)**

**(e) Relationship between the remuneration policy and group performance (continued)**

No dividends have been paid for the five years to 30 June 2017.

	30 June 2017	30 June 2016 Restated	30 June 2015	30 June 2014	30 June 2013
	\$	\$	\$	\$	\$
Share price at start of the year	0.190*	0.300*	0.230*	0.300*	4.00*
Share price at end of year	0.185*	0.190*	0.300*	0.230*	0.300*
Basic and diluted gain/(loss) per share (cents)	(6.61)*	(9.43)*	(11.20)*	(10.00)*	(82.00)*

\* On 3 May 2017 the share capital of the Company has been consolidated through the conversion of every ten shares into one share. Basic and diluted loss per share for the prior financial year have been restated to align with the current year's amount.

For personal use only

**Rhinomed Limited**  
**Directors' report**  
**30 June 2017**  
(continued)

**Remuneration report (continued)**

**(f) Key management personnel disclosures**

*Shareholding*

The number of shares in the parent entity held during the financial year by each director and other members of key management personnel of the consolidated entity, including their personally related parties, is set out below:

2017	Balance at start of year	Balance at date of appointment	Consolidation 10:1	Received as part of remuneration	Additions	Disposals/ other	Balance at date of resignation	Balance at end of year
<b>Ordinary shares</b>								
Michael Johnson	1,611,014	-	161,101	-	13,452	-	-	174,553
Ron Dewhurst	71,000,000	-	7,100,000	-	84,680	-	-	7,184,680
Brent Scrimshaw	759,177	-	75,918	-	-	-	-	75,918
Eric Knight	761,572	-	76,158	-	-	-	-	76,158
Justine Heath <sup>1</sup>	-	-	-	-	-	-	-	-
Shane Duncan	300,000	-	30,000	-	-	-	-	30,000
<b>Total</b>	<b>74,431,763</b>	-	<b>7,443,177</b>	-	<b>98,132</b>	-	-	<b>7,541,309</b>

**Rhinomed Limited**  
**Directors' report**  
**30 June 2017**  
(continued)

**Remuneration report (continued)**

**(f) Key management personnel disclosures (continued)**

*Shareholding (continued)*

2016	Balance at start of year	Balance at date of appointment	Consolidation 10:1	Received as part of remuneration	Additions	Disposals/ other	Balance at date of resignation	Balance at end of year
<b>Ordinary shares</b>								
Michael Johnson	1,611,014	-	-	-	-	-	-	1,611,014
Martin Rogers <sup>2</sup>	3,428,573	-	-	-	-	-	3,428,573	-
Ron Dewhurst <sup>3</sup>	-	50,000,000	-	-	21,000,000	-	-	71,000,000
Brent Scrimshaw	759,177	-	-	-	-	-	-	759,177
Eric Knight	761,572	-	-	-	-	-	-	761,572
Justine Heath	-	-	-	-	-	-	-	-
Shane Duncan	-	300,000	-	-	-	-	-	300,000
<b>Total</b>	<b>6,560,336</b>	<b>50,300,000</b>	-	-	<b>21,000,000</b>	-	<b>3,428,573</b>	<b>74,431,763</b>

<sup>1</sup> Justine Heath resigned as Chief Financial Officer and Chief Operating Officer on 24 October 2016

<sup>2</sup> Martin Rogers resigned as Non-Executive Chairman on 1 December 2015

<sup>3</sup> Ron Dewhurst appointed as Non-Executive Chairman on 1 December 2015

*Option holding*

The number of options over ordinary shares in the parent entity held during the financial year by each director and other members of key management personnel of the consolidated entity, including their personally related parties, is set out below:

**Rhinomed Limited**  
**Directors' report**  
**30 June 2017**  
(continued)

**Remuneration report (continued)**

**(f) Key management personnel disclosures (continued)**

*Option holding (continued)*

2017	Balance at start of year	Balance at date of appointment	Granted and vested	Acquired on market	Exercised	Expired/ forfeited	Consolidation 10:1	Balance at date of resignation	Balance at end of year
<b>Ordinary shares</b>									
Michael Johnson	40,273,056	-	4,000,000	-	-	(40,273,056)	-	-	4,000,000
Ron Dewhurst	10,000,000	-	-	-	-	-	1,000,000	-	1,000,000
Brent Scrimshaw	10,000,000	-	1,000,000	-	-	(10,000,000)	-	-	1,000,000
Eric Knight	10,000,000	-	1,000,000	-	-	(10,000,000)	-	-	1,000,000
Justine Heath <sup>2</sup>	5,000,000	-	-	-	-	-	-	5,000,000	-
Shane Duncan	5,000,000	-	-	-	-	-	500,000	-	500,000
<b>Total</b>	<b>80,273,056</b>	<b>-</b>	<b>6,000,000</b>	<b>-</b>	<b>-</b>	<b>(60,273,056)</b>	<b>1,500,000</b>	<b>5,000,000</b>	<b>7,500,000</b>

2016	Balance at start of year	Balance at date of appointment	Granted and vested	Acquired on market	Exercised	Expired/ forfeited	Consolidation 10:1	Balance at date of resignation	Balance at end of year <sup>1</sup>
<b>Ordinary shares</b>									
Michael Johnson	40,273,056	-	-	-	-	-	-	-	40,273,056
Martin Rogers <sup>3</sup>	34,700,000	-	-	-	-	-	-	34,700,000	-
Ron Dewhurst <sup>4</sup>	-	-	10,000,000	-	-	-	-	-	10,000,000
Brent Scrimshaw	10,000,000	-	-	-	-	-	-	-	10,000,000
Eric Knight	10,000,000	-	-	-	-	-	-	-	10,000,000
Justine Heath	-	-	5,000,000	-	-	-	-	-	5,000,000
Shane Duncan	-	-	5,000,000	-	-	-	-	-	5,000,000
<b>Total</b>	<b>94,973,056</b>	<b>-</b>	<b>20,000,000</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>34,700,000</b>	<b>80,273,056</b>

<sup>1</sup>: All options fully vested and exercisable at the end of the year

**Rhinomed Limited**  
**Directors' report**  
**30 June 2017**  
(continued)

**Remuneration report (continued)**

**(f) Key management personnel disclosures (continued)**

*Option holding (continued)*

<sup>2</sup> Justine Health resigned on 24 October 2016 (pre-consolidation 10:1)

<sup>3</sup> Martin Rogers resigned as Non-Executive Chairman on 1 December 2015

<sup>4</sup> Ron Dewhurst appointed as Non-Executive Chairman on 1 December 2015

*Related party transactions*

Disclosures relating to remuneration of key management personnel are set out in note 13 and the remuneration report in the Directors' report.

	Note	Consolidated	
		30 June 2017	30 June 2016
Transactions with related parties (the following transactions occurred with the following related parties):			
Payment for goods and services:			
Smart Street	(i)	96,400	50,572

(i) Consulting fees paid to Smart Street, Director related entity to Mr Michael Johnston.

**Receivable from and payable to related parties**

Balance outstanding at the end of the current year to Smart Street is \$9,540 (2016: \$5,968). Smart Street provides consulting and marketing related services to the Company.

There are no other outstanding balances at the reporting date in relation to transactions with related parties.

**[This concludes the remuneration report, which has been audited]**

**Rhinomed Limited**  
**Directors' report**  
**30 June 2017**  
(continued)

## Shares under option

### Unissued ordinary shares

Unissued ordinary shares of Rhinomed Limited under option at the date of this report are as follows:

Grant date	Consolidation date	Expiry date	Exercise price	Options expired	Consolidation 10:1	Number under option
27/05/2013	-	30/04/2017	\$0.060	(95,400,000)	-	-
18/11/2013	-	30/04/2017	\$0.060	(15,250,000)	-	-
11/04/2014	-	30/04/2017	\$0.060	(2,500,000)	-	-
11/04/2014	-	30/04/2017	\$0.065	(40,000,000)	-	-
23/09/2015	-	30/04/2017	\$0.060	(90,000,000)	-	-
23/12/2015	03/05/2017	30/04/2019	\$0.650*	-	76,923	76,923
11/04/2016	03/05/2017	11/04/2019	\$0.650*	-	1,800,000	1,800,000
20/05/2016	03/05/2017	30/04/2019	\$0.670*	-	1,000,000	1,000,000
24/01/2017	-	30/12/2020	\$0.400	-	-	150,000
28/04/2017	-	30/04/2020	\$0.270	-	-	6,000,000
<b>Total</b>				<b>(243,150,000)</b>	<b>2,876,923</b>	<b>9,026,923</b>

\* Post consolidation

No person entitled to exercise the options had or has any right by virtue of the option to participate in any share issue of the Company or of any other body corporate. There have been no unissued shares or interest under option of any controlled entity within the Group during or since the end of the reporting period.

## Indemnity and insurance of officers

The Company has indemnified the Director and executives of the Company for costs incurred, in their capacity as a Director or executive, for which they may be held personally liable, except where there is a lack of good faith.

During the financial year, the Company paid a premium in respect of a contract to insure the Directors and executives of the Company against a liability to the extent permitted by the *Corporations Act 2001*. The contract of insurance prohibits disclosure of the nature of liability and the amount of the premium.

## Indemnity and insurance of auditor

The Company has not, during or since the financial year, indemnified or agreed to indemnify the auditor of the Company or any related entity against a liability incurred by the auditor.

During the financial year, the Company has not paid a premium in respect of a contract to insure the auditor of the Company or any related entity.

## Proceedings on behalf of the company

No person has applied to the Court under section 237 of the *Corporations Act 2001* for leave to bring proceedings on behalf of the Company, or to intervene in any proceedings to which the Company is a party, for the purpose of taking responsibility on behalf of the Company for all or part of those proceedings.

## Environmental issues

The Group's operations are not affected by environmental regulations in Australia.

**Rhinomed Limited**  
**Directors' report**  
**30 June 2017**  
(continued)

## **Event since the end of the financial year**

On 19 July 2017, The Company announced that it had received purchase orders confirming US Pharmacy giant Walgreens had placed Rhinomed's 4 SKU product range (Trial, Small, Medium and Large pack) of the MUTE sleep and breathing technology product in approximately 4,300 pharmacy/drugstores across the USA. In addition, the Hamacher Resource Group confirmed that 2 of the Mute range (Trial and Medium) would be included in their planogram. This planogram is utilised by some 10,000 independent pharmacy/drugstores throughout the USA.

No other matter or circumstance has arisen since 30 June 2017 that has significantly affected, or may significantly affect the Group's operations, the results of those operations, or the Groups state of affairs in future financial years.

## **Non-audit service**

Details of the amounts paid or payable to the auditor for non-audit services provided during the financial year by the auditor are outlined in note 15 to the financial statements.

The directors are satisfied that the provision of non-audit services during the financial year, by the auditor (or by another person or firm on the auditor's behalf), is compatible with the general standard of independence for auditors imposed by the *Corporations Act 2001*.

## **Auditor's independence declaration**

A copy of the auditor's independence declaration as required under section 307C of the *Corporations Act 2001* is set out on the following page.

## **Auditor**

HLB Mann Judd continues in office in accordance with section 327 of the *Corporations Act 2001*.

This report, incorporating the audited remuneration report, is made in accordance with a resolution of directors, pursuant to section 298(2)(a) of the *Corporations Act 2001*.

On behalf of the Directors



Michael Johnson  
Director

Melbourne  
28 September 2017



**AUDITOR'S INDEPENDENCE DECLARATION**

As lead auditor for the audit of the consolidated financial report of Rhinomed Limited for the year ended 30 June 2017, I declare that, to the best of my knowledge and belief, there have been no contraventions of:

- (a) the auditor independence requirements as set out in the *Corporations Act 2001* in relation to the audit; and
- (b) any applicable code of professional conduct in relation to the audit.

This declaration is in relation to Rhinomed Limited and the entities it controlled during the year.

*HLB Mann Judd*

**HLB Mann Judd**  
**Chartered Accountants**

Melbourne  
28 September 2017

*Nick Walker*

**Nick Walker**  
**Partner**

**HLB Mann Judd (VIC Partnership)**

Level 9, 575 Bourke Street, Melbourne VIC 3000 | GPO Box 2850, Melbourne VIC 3001 | DX 154 Melbourne | Tel: +61 (0)3 9606 3888 | Fax: +61 (0)3 9606 3800

Email: [mailbox@hlbvic.com.au](mailto:mailbox@hlbvic.com.au) | Website: [www.hlbvic.com.au](http://www.hlbvic.com.au)

Liability limited by a scheme approved under Professional Standards Legislation

For personal use only

**Rhinomed Limited**  
**Corporate governance statement**  
**30 June 2017**

**Corporate governance statement**

Rhinomed Limited ('the Company') and the Board of Directors are committed to achieving the highest standards of corporate governance. The Board continues to review the framework and practices to ensure they meet the interests of shareholders. The Company and its controlled entities together are referred to as the Group in this statement.

A description of the Groups main corporate governance practices is set out on the Company's website [www.rhinomed.global](http://www.rhinomed.global). All these practices, unless otherwise stated, were in place for the entire year and comply with the ASX Corporate Governance Principles and Recommendations.

For personal use only

**Rhinomed Limited**  
**Consolidated statement of profit or loss and other comprehensive income**  
**For the year ended 30 June 2017**

	Note	Consolidated entity 2017 \$	2016 \$
<b>Income</b>			
Revenue from continuing operations	2	1,717,225	1,012,433
Other income	2	25,090	84,882
<b>Expenses</b>			
Raw materials and consumables used	3	(388,309)	(312,375)
Employee benefits expense		(2,198,595)	(1,855,783)
Depreciation and amortisation	3	(470,228)	(527,315)
Impairment of assets		-	(1,622)
Fair value adjustment of investment		-	(25,000)
Administration		(1,399,803)	(1,412,979)
Marketing		(1,510,672)	(2,372,521)
Research and development		(64,546)	(234,269)
Other expenses		(542,639)	(791,437)
<b>Loss before income tax</b>		<b>(4,832,477)</b>	<b>(6,435,986)</b>
Income tax benefit	4	390,899	437,457
<b>Loss for the year</b>		<b>(4,441,578)</b>	<b>(5,998,529)</b>
<b>Other comprehensive loss</b>			
Exchange differences on translation of foreign operations	7(b)	(4,961)	(24,024)
<b>Total comprehensive loss for the year</b>		<b>(4,446,539)</b>	<b>(6,022,553)</b>
Total comprehensive loss for the year is attributable to:			
Non-controlling interests		-	-
Owners of Rhinomed Limited		(4,446,539)	(6,022,553)
		<b>Cents</b>	<b>Cents (restated)<sup>2</sup></b>
<b>Loss per share for loss from continuing operations attributable to the ordinary equity holders of the Company:</b>			
Basic earnings per share <sup>1</sup>	16	(6.61)	(9.43)
Diluted earnings per share <sup>1</sup>	16	(6.61)	(9.43)

<sup>1</sup> On 3 May 2017 the share capital of the Company has been consolidated through the conversion to one share for every ten shares.

<sup>2</sup> Basic and diluted loss per share for the prior financial year have been restated to align with the current year's amount based on post consolidation of one share for every ten shares held.

*The above consolidated statement of profit or loss and other comprehensive income should be read in conjunction with the accompanying notes.*

For personal use only

**Rhinomed Limited**  
**Consolidated statement of financial position**  
**As at 30 June 2017**

	Note	Consolidated entity 2017 \$	2016 \$
<b>ASSETS</b>			
<b>Current assets</b>			
Cash and cash equivalents	5(a)	1,666,883	2,612,757
Trade and other receivables	5(b)	514,275	510,645
Inventories	5(c)	429,118	546,337
Other assets		78,032	149,235
<b>Total current assets</b>		<u>2,688,308</u>	<u>3,818,974</u>
<b>Non-current assets</b>			
Other financial assets		51,475	103,775
Property, plant and equipment		23,926	127,811
Intangible assets	6(a)	3,678,251	4,039,879
<b>Total non-current assets</b>		<u>3,753,652</u>	<u>4,271,465</u>
<b>Total assets</b>		<u>6,441,960</u>	<u>8,090,439</u>
<b>LIABILITIES</b>			
<b>Current liabilities</b>			
Trade and other payables	5(e)	979,615	895,818
Provisions	6(b)	122,632	79,251
<b>Total current liabilities</b>		<u>1,102,247</u>	<u>975,069</u>
<b>Non-current liabilities</b>			
Provisions	6(b)	7,620	-
<b>Total non-current liabilities</b>		<u>7,620</u>	<u>-</u>
<b>Total liabilities</b>		<u>1,109,867</u>	<u>975,069</u>
<b>Net assets</b>		<u>5,332,093</u>	<u>7,115,370</u>
<b>EQUITY</b>			
Issued capital	7(a)	50,934,839	48,919,157
Reserves	7(b)	795,104	3,605,594
Non-controlling interest reserve	7(b)	(6,158,687)	(6,158,687)
Accumulated losses	7(c)	(40,239,163)	(39,250,694)
<b>Total equity</b>		<u>5,332,093</u>	<u>7,115,370</u>

*The above consolidated statement of financial position should be read in conjunction with the accompanying notes.*

For personal use only

**Rhinomed Limited**  
**Consolidated statement of changes in equity**  
**For the year ended 30 June 2017**

Note	Issued capital \$	Option reserve \$	Reserves NCI \$	Foreign exchange reserve \$	Accumulated losses \$	Total equity \$
<b>Balance at 1 July 2015</b>	41,927,021	3,624,910	(6,158,687)	-	(33,425,765)	5,967,479
Loss for the year	-	-	-	-	(5,998,529)	(5,998,529)
Other comprehensive expense for the year	-	-	-	(24,024)	-	(24,024)
<b>Total comprehensive loss for the year</b>	-	-	-	<b>(24,024)</b>	<b>(5,998,529)</b>	<b>(6,022,553)</b>
<b>Transactions with equity holders in their capacity as equity holders:</b>						
Shares issued net of issue costs	6,992,136	-	-	-	-	6,992,136
Options expired	-	(173,600)	-	-	173,600	-
Options issued	-	178,308	-	-	-	178,308
	6,992,136	4,708	-	-	173,600	7,170,444
<b>Balance at 30 June 2016</b>	<b>48,919,157</b>	<b>3,629,618</b>	<b>(6,158,687)</b>	<b>(24,024)</b>	<b>(39,250,694)</b>	<b>7,115,370</b>
Loss for the year	-	-	-	-	(4,441,578)	(4,441,578)
Other comprehensive expense for the year	-	-	-	(4,961)	-	(4,961)
<b>Total comprehensive loss for the year</b>	-	-	-	<b>(4,961)</b>	<b>(4,441,578)</b>	<b>(4,446,539)</b>
<b>Transactions with equity holders in their capacity as equity holders:</b>						
Shares issued net of issue costs	2,015,682	-	-	-	-	2,015,682
Options expired	-	(3,453,109)	-	-	3,453,109	-
Options issued	-	647,580	-	-	-	647,580
	2,015,682	(2,805,529)	-	-	3,453,109	2,663,262
<b>Balance at 30 June 2017</b>	<b>50,934,839</b>	<b>824,089</b>	<b>(6,158,687)</b>	<b>(28,985)</b>	<b>(40,239,163)</b>	<b>5,332,093</b>

The above consolidated statement of changes in equity should be read in conjunction with the accompanying notes.

For personal use only

**Rhinomed Limited**  
**Consolidated statement of cash flows**  
**For the year ended 30 June 2017**

	<b>Consolidated entity</b>	
	<b>2017</b>	<b>2016</b>
Note	\$	\$
<b>Cash flows from operating activities</b>		
Receipts from customers	2,024,000	845,323
Payments to suppliers and employees	(5,432,071)	(7,416,624)
Interest received	35,000	23,605
Interest and other costs of finance paid	(14,000)	(14,776)
Receipt of R&D tax refund	279,860	437,457
Government grants	110,955	-
<b>Net cash outflow from operating activities</b>	<b>8(a) (2,996,256)</b>	<b>(6,125,015)</b>
<b>Cash flows from investing activities</b>		
Payments for purchase of property, plant and equipment	(4,714)	(20,004)
Proceeds from sale of equity investments	-	310,125
Proceeds from sale of intellectual property	-	104,500
Withdrawal/(investment) from/(in) term deposits	51,510	-
<b>Net cash inflow from investing activities</b>	<b>46,796</b>	<b>394,621</b>
<b>Cash flows from financing activities</b>		
Proceeds from issues of shares and other equity securities	7(a) 2,198,440	7,232,589
Capital raising costs	(182,758)	(240,453)
<b>Net cash inflow from financing activities</b>	<b>2,015,682</b>	<b>6,992,136</b>
<b>Net (decrease)/ increase in cash and cash equivalents</b>	<b>(933,778)</b>	<b>1,261,742</b>
Cash and cash equivalents at the beginning of the year	2,612,757	1,368,621
Effects of exchange rate changes on cash and cash equivalents	(12,096)	(17,606)
<b>Cash and cash equivalents at end of year</b>	<b>5(a) 1,666,883</b>	<b>2,612,757</b>

*The above consolidated statement of cash flows should be read in conjunction with the accompanying notes.*

**Rhinomed Limited**  
**Note to the consolidated financial statements**  
**30 June 2017**

**1 Segment information**

The Group has operated in one segment, being the identification, acquisition and commercialisation of late stage therapeutic delivery technologies. The segment details are therefore fully reflected in the body of the financial report.

**2 Revenue**

	<b>Consolidated entity</b>	
	<b>2017</b>	<b>2016</b>
	\$	\$
<b>Revenue</b>		
Sale of goods	1,717,225	1,012,433
<b>Other income</b>		
Interest received	25,090	23,605
Gain on sale of equity investment	-	60,125
Other items	-	1,152
	<u>25,090</u>	<u>84,882</u>
<b>Total revenue and other income</b>	<u>1,742,315</u>	<u>1,097,315</u>

**3 Expenses**

	<b>Consolidated entity</b>	
	<b>2017</b>	<b>2016</b>
	\$	\$
<b>Profit/loss before income tax from continuing operations includes the following specific expenses:</b>		
<b>Cost of sales</b>		
Raw materials and consumables used	388,309	312,375
<b>Depreciation and amortisation</b>		
Plant and equipment	108,600	164,697
Intangible asset	361,628	362,618
	<u>470,228</u>	<u>527,315</u>
<b>Impairment</b>		
Assets	-	-
Inventory	-	1,622
	<u>-</u>	<u>1,622</u>
<b>Finance costs</b>		
Finance costs expensed	-	-
<b>Net foreign exchange loss</b>		
Foreign exchange loss	16,317	67,508

For personal use only

**Rhinomed Limited**  
**Note to the consolidated financial statements**  
**30 June 2017**  
(continued)

**3 Expenses (continued)**

	<b>Consolidated entity</b>	
	<b>2017</b>	<b>2016</b>
	<b>\$</b>	<b>\$</b>
<b>Superannuation expense</b>		
Defined contribution superannuation expense	<b>64,634</b>	56,239
<b>Research and development costs</b>		
Research and development	<b>64,546</b>	234,269
<b>Operating lease expense</b>		
Operating lease expense	<b>103,808</b>	109,413

**4 Income tax benefit**

**(a) Numerical reconciliation of income tax benefit to prima facie tax payable**

	<b>Consolidated entity</b>	
	<b>2017</b>	<b>2016</b>
	<b>\$</b>	<b>\$</b>
Loss before income tax expense	<b>(4,832,477)</b>	(6,435,986)
Tax at the Australian tax rate of 27.5% (2016: 30%)	<b>(1,328,931)</b>	(1,930,796)
<b>Tax effect of amounts which are not deductible in calculating income tax:</b>		
Impairment and amortisation expenses	<b>99,448</b>	116,286
Other expenses not deductible	<b>799</b>	4,150
Legal fees and penalties	<b>669</b>	15,673
Other deductible items	<b>(50,258)</b>	(72,136)
Deferred tax assets relating to tax losses not recognised	<b>1,669,172</b>	2,304,280
<b>Income tax benefit</b>	<b>390,899</b>	<b>437,457</b>

**(b) Unrecognised temporary differences**

	<b>Consolidated entity</b>	
	<b>2017</b>	<b>2016</b>
	<b>\$</b>	<b>\$</b>
Tax losses	<b>18,960,777</b>	17,291,604
Inventory	<b>(104,217)</b>	(132,162)
Prepayments	<b>(41,705)</b>	(76,510)
Accruals	<b>39,552</b>	23,494
Unearned income	<b>51,492</b>	66,894
Employee provisions	<b>33,724</b>	23,775
<b>Net deferred tax assets not recognised</b>	<b>18,939,623</b>	<b>17,197,095</b>

For personal use only



**Rhinomed Limited**  
**Note to the consolidated financial statements**  
**30 June 2017**  
(continued)

**5 Financial assets and financial liabilities**

**(a) Cash and cash equivalents**

	<b>Consolidated entity</b>	
	<b>2017</b>	<b>2016</b>
	<b>\$</b>	<b>\$</b>
Cash at bank	<b>1,666,883</b>	2,612,757
	<b>1,666,883</b>	<b>2,612,757</b>

Refer to note 9(e)(iv) for the effective interest rate.

**(b) Trade and other receivables**

	<b>Consolidated entity</b>	
	<b>2017</b>	<b>2016</b>
	<b>Current</b>	<b>Current</b>
	<b>\$</b>	<b>\$</b>
Trade receivables	<b>514,275</b>	502,683
Other receivables	-	140,962
Less: Provision for impairment of receivables	-	(133,000)
	<b>514,275</b>	<b>510,645</b>

*Impairment of receivables*

The consolidated entity has recognised a loss of \$nil (2016: \$nil) in profit or loss in respect of impairment of receivables for the year ended 30 June 2017.

	<b>Consolidated entity</b>	
	<b>2017</b>	<b>2016</b>
	<b>\$</b>	<b>\$</b>
<b>Movements in the provision for impairment of receivables are as follows:</b>		
Opening balance	(133,000)	(133,000)
Additional provisions recognised	-	-
Receivables written off during the year as uncollectible	133,000	-
<b>Closing balance</b>	<b>-</b>	<b>(133,000)</b>

*Past due but not impaired*

Customers with balances past due but without provision for impairment of receivables amount to \$nil as at 30 June 2017 (\$nil as at 30 June 2016).

**(c) Inventories**

Inventories consist of finished goods and are measured at cost.

For personal use only

**Rhinomed Limited**  
**Note to the consolidated financial statements**  
**30 June 2017**  
(continued)

**5 Financial assets and financial liabilities (continued)**

**(d) Other financial assets**

	<b>Consolidated entity</b>	
	<b>2017</b>	<b>2016</b>
	\$	\$
Term deposits*	<u>51,475</u>	103,775
	<u><b>51,475</b></u>	<u><b>103,775</b></u>

\* Represents term deposits held in relation to a rental property lease and credit card facilities.

**(e) Trade and other payables**

	<b>Consolidated entity</b>	
	<b>2017</b>	<b>2016</b>
	\$	\$
<b>Unsecured</b>		
Trade payables	297,347	404,862
Other payables	<u>682,268</u>	490,956
	<u><b>979,615</b></u>	<u><b>895,818</b></u>

Trade payables are unsecured and are usually paid within 30 days of recognition.

The carrying amounts of trade and other payables are assumed to be the same as their fair values, due to their short-term nature.

**6 Non-financial assets and liabilities**

**(a) Intangible assets**

	<b>Consolidated entity</b>	
	<b>2017</b>	<b>2016</b>
	\$	\$
<b>Goodwill</b>		
At cost	4,951,996	4,951,996
Less: impairment	<u>(3,386,992)</u>	(3,386,992)
<b>Net carrying value</b>	<u><b>1,565,004</b></u>	<u><b>1,565,004</b></u>
<b>Development costs</b>		
At cost	602,503	602,503
Less: impairment	<u>(213,576)</u>	(213,576)
Less: amortisation	<u>(134,936)</u>	(104,248)
<b>Net carrying value</b>	<u><b>253,991</b></u>	<u><b>284,679</b></u>

For personal use only

**Rhinomed Limited**  
**Note to the consolidated financial statements**  
**30 June 2017**  
(continued)

**6 Non-financial assets and liabilities (continued)**

**(a) Intangible assets (continued)**

	Consolidated entity	
	2017	2016
	\$	\$
<b>Intellectual property</b>		
At cost	9,516,217	9,516,217
Less: impairment	(6,492,957)	(6,492,957)
Less: amortisation	(1,164,004)	(833,064)
<b>Net carrying value</b>	<b>1,859,256</b>	<b>2,190,196</b>
<b>Total intangible assets</b>	<b>3,678,251</b>	<b>4,039,879</b>

*(i) Reconciliations*

Reconciliations of the written down values at the beginning and end of the current and previous financial year are set out below:

	Goodwill	Development costs	Intellectual property	Total
	\$	\$	\$	\$
<b>Balance at 1 July 2015</b>	1,565,004	326,010	2,511,483	4,402,497
Amortisation charge	-	(41,331)	(321,287)	(362,618)
<b>Balance at 30 June 2016</b>	<b>1,565,004</b>	<b>284,679</b>	<b>2,190,196</b>	<b>4,039,879</b>
Amortisation charge	-	(30,688)	(330,940)	(361,628)
<b>Balance at 30 June 2017</b>	<b>1,565,004</b>	<b>253,991</b>	<b>1,859,256</b>	<b>3,678,251</b>

*(ii) Impairment of intangibles*

The Directors conducted an impairment review of the Group's intangible assets as at 30 June 2017 and concluded that an impairment charge was not necessary. The Directors have assessed that IP and development costs have an indefinite life until they are commercialised. They, together with goodwill have been subject to an impairment test whereby the recoverable amount was compared to their written down value. Recoverable amount has been determined by the Board by preparing a value in use calculation using cashflow projections over a four year period with a terminal value calculated on a perpetual growth basis, a fair value calculation using cashflow projections over a four year period applying a terminal value on EBIT multiple basis, and taking the higher of the two in line with Australian Accounting Standards. The cashflows were discounted using a pre-tax discount rate of 20 percent (2016: 20 percent) at the beginning of the projection period. The budget reflected the Board's best estimate of the product's expected market share and the Group's revenue stream. Gross profit was determined taking into account expected cost structures as well as estimated inflation rates over the period (a reasonably possible change in the discount rate would not lead to an impairment of the intangible assets).

In performing the impairment review, the Directors have determined that the cash generating unit (CGU) is to be assessed on a group level, inline with the Group's single segment.

**Rhinomed Limited**  
**Note to the consolidated financial statements**  
**30 June 2017**  
(continued)

**6 Non-financial assets and liabilities (continued)**

**(a) Intangible assets (continued)**

*(iii) Amortisation*

As the Group has commenced commercialisation of the BreatheAssist technology, an amortisation charge is recognised for development costs and intellectual property over the asset's useful life. An amortisation charge is recognised for \$361,628 (2016: \$362,618) and was recorded for the period.

The intangible assets has been assessed as having a finite life and is amortised using the straight line method over a period of 9.5 years for 2017 and 2016.

**(b) Provisions**

	<b>Consolidated entity</b>	
	<b>2017</b>	<b>2016</b>
	\$	\$
<b>Current</b>		
Employee benefits	<b>122,632</b>	79,251
	<b>122,632</b>	<b>79,251</b>

	<b>Consolidated entity</b>	
	<b>2017</b>	<b>2016</b>
	\$	\$
<b>Non-current</b>		
Employee benefits	<b>7,620</b>	-
	<b>7,620</b>	-

*(i) Provision for employee benefits*

Provision for employee benefits represents amounts accrued for annual leave and long service leave.

The current portion for this provision includes the total amount accrued for annual leave entitlements and the amounts accrued for long service leave entitlements that have vested due to employees having completed the required period of service. Based on past experience, the Group does not expect the full amount of annual leave or long service leave balances classified as current liabilities to be settled within the next 12 months. However, these amounts must be classified as current liabilities since the Group does not have an unconditional right to defer the settlement of these amounts in the event employees wish to use their leave entitlement.

The non-current portion for this provision includes amounts accrued for long service leave entitlements that have not yet vested in relation to those employees who have not yet completed the required period of service.

In calculating the present value of future cash flows in respect of long service leave, the probability of long service leave being taken is based on historical data. The measurement and recognition criteria relating to employee benefits have been discussed in note 20.

For personal use only

**Rhinomed Limited**  
**Note to the consolidated financial statements**  
**30 June 2017**  
(continued)

**7 Equity**

**(a) Issued capital**

(i) *Movements in ordinary shares on issue:*

Details	Number of shares	\$
<b>Balance at 1 July 2015</b>	<b>539,438,635</b>	<b>41,927,021</b>
23/09/2015 Private placement at \$0.032	64,062,500	2,050,000
25/09/2015 Private placement at \$0.032	10,937,500	350,000
23/12/2015 Private placement at \$0.032	4,687,500	150,000
11/03/2016 Private placement at \$0.024	139,583,340	3,350,000
20/05/2016 Private placement at \$0.024	55,524,532	1,332,589
Less: transaction costs arising on share issue	-	(240,453)
<b>Balance at 30 June 2016</b>	<b>814,234,007</b>	<b>48,919,157</b>
14/03/2017 Private placement at \$0.018	105,135,000	1,892,430
20/03/2017 Private placement at \$0.018	13,000,000	234,000
21/03/2017 Private placement at \$0.018	4,000,000	72,000
23/03/2017 Private placement at \$0.10	100	10
03/05/2017 Share consolidation	(936,369,107)	-
03/05/2017 Share consolidation	93,637,159	-
Less: transaction costs arising on share issue	-	(182,758)
<b>Balance at 30 June 2017</b>	<b>93,637,159</b>	<b>50,934,839</b>

**(b) Reserves**

	Consolidated entity	
	2017	2016
	\$	\$
Other reserves	<b>824,089</b>	3,629,618
Foreign exchange reserve	<b>(28,985)</b>	(24,024)
	<b>795,104</b>	<b>3,605,594</b>

**Rhinomed Limited**  
**Note to the consolidated financial statements**  
**30 June 2017**  
(continued)

**7 Equity (continued)**

**(b) Reserves (continued)**

*(i) Reconciliations*

	Option reserve \$	NCI reserve \$	Foreign exchange reserve \$	Total \$
<b>Balance at 1 July 2015</b>	<b>3,624,910</b>	<b>(6,158,687)</b>	-	<b>(2,533,777)</b>
Share-based payments	-	-	-	-
Options issued/(expired)	4,708	-	-	4,708
Foreign exchange movements	-	-	(24,024)	(24,024)
<b>Balance at 30 June 2016</b>	<b>3,629,618</b>	<b>(6,158,687)</b>	<b>(24,024)</b>	<b>(2,553,093)</b>
<b>Balance at 30 June 2016</b>	<b>3,629,618</b>	<b>(6,158,687)</b>	<b>(24,024)</b>	<b>(2,553,093)</b>
Share-based payments	-	-	-	-
Options issued/(expired)	(2,805,529)	-	-	(2,805,529)
Foreign exchange movements	-	-	(4,961)	(4,961)
<b>Balance at 30 June 2017</b>	<b>824,089</b>	<b>(6,158,687)</b>	<b>(28,985)</b>	<b>(5,363,583)</b>

The option reserve is used to record the expense associated with the valuation of options. The NCI reserve is used to record adjustments arising from transactions with non-controlling interests. The foreign exchange reserve is used to record exchange differences arising on translation of a foreign controlled subsidiary.

*(ii) Movements in options*

	No.	\$
<b>Balance at 1 July 2015</b>	<b>245,150,000</b>	<b>3,624,910</b>
Options lapsed/expired	(2,000,000)	(173,600)
Options issued	28,769,230	178,308
<b>Balance 30 June 2016</b>	<b>271,919,230</b>	<b>3,629,618</b>
Options lapsed/expired	(243,150,000)	(3,453,109)
Consolidation 10:1	(25,892,307)	-
Options issued	6,150,000	647,580
<b>Balance at 30 June 2017</b>	<b>9,026,923</b>	<b>824,089</b>

**Rhinomed Limited**  
**Note to the consolidated financial statements**  
**30 June 2017**  
(continued)

**7 Equity (continued)**

**(b) Reserves (continued)**

*(ii) Movements in options (continued)*

On 24 January 2017, the Company has issued 150,000 of options to its employees and on 28 April 2017 the Company has issued 6,000,000 of options to its key management personnel. The options are not listed and expire on the 30 December 2020 and 30 April 2020 respectively. The options have an exercise price of \$0.040 and \$0.027. The fair value of the options granted during the year was \$0.0972 and \$0.1055.

**(c) Accumulated losses**

	<b>Consolidated entity</b>	
	<b>2017</b>	<b>2016</b>
	\$	\$
Accumulated losses at the beginning of the financial year	<b>39,250,694</b>	33,425,765
Loss after income tax expense for the year	<b>4,441,578</b>	5,998,529
Transfer from option reserve	<b>(3,453,109)</b>	(173,600)
	<b>(40,239,163)</b>	<b>(39,250,694)</b>

**8 Cash flow information**

**(a) Reconciliation of profit after income tax to net cash inflow from operating activities**

	<b>Consolidated entity</b>	
	<b>2017</b>	<b>2016</b>
	\$	\$
<b>Loss for the period</b>	<b>(4,441,578)</b>	<b>(5,998,529)</b>
Adjustment for:		
Depreciation and amortisation	<b>470,228</b>	527,315
(Gain)/loss on disposal of assets	-	(61,277)
Share-based payments	<b>647,580</b>	-
Other	<b>12,096</b>	178,307
Fair value adjustments of investments	-	25,000
Change in operating assets and liabilities:		
(Increase)/decrease in trade and other receivables	<b>(2,839)</b>	(338,393)
(Increase)/decrease in other current assets	<b>71,203</b>	(584,128)
(Increase)/decrease in accounts payable	<b>78,835</b>	81,397
(Increase)/decrease in other liabilities	-	45,293
(Increase)/decrease in inventories	<b>117,219</b>	-
(Increase)/decrease in employee benefits	<b>51,000</b>	-
<b>Net cash inflow/ (outflow) from operating activities</b>	<b>(2,996,256)</b>	<b>(6,125,015)</b>

**(b) Non-cash investing and financing activities**

During the current and prior year, there were no non-cash financing activities.

For personal use only

**Rhinomed Limited**  
**Note to the consolidated financial statements**  
**30 June 2017**  
(continued)

**9 Financial risk management**

**(a) Financial instruments**

The Group's financial instruments are detailed below:

	Note	Consolidated entity	
		2017	2016
		\$	\$
Cash and cash equivalents	5(a)	1,666,883	2,612,757
Trade and other receivables	5(b)	514,275	510,645
Other financial assets	5(d)	51,475	103,775
Trade and other payables	5(e)	(979,615)	(895,818)
		1,253,018	2,331,359

The Group did not have any derivative instruments at 30 June 2017 and 30 June 2016.

**(b) Risk management policy**

The Board is responsible for overseeing the establishment and implementation of the risk management system, and reviews and assesses the effectiveness of the Group's implementation of that system on a regular basis.

The Board and Senior Management identify the general areas of risk and their impact on the activities of the Group, with Management performing a regular review of:

- the major risks that occur within the business;
- the degree of risk involved;
- the current approach to managing the risk; and
- if appropriate, determine:
  - any inadequacies of the current approach; and
  - possible new approaches that more efficiently and effectively address the risk.

Management reports risks identified to the Board through the monthly Operations Report.

The Group seeks to ensure that its exposure to undue risk which is likely to impact its financial performance, continued growth and survival is minimised in a cost effective manner.

**(c) Significant accounting policy**

Details of significant accounting policies and methods adopted, including the criteria for recognition, the basis for measurement and the basis on which income and expenses are recognised, in respect of each class of financial asset, financial liability and equity instrument are disclosed in note 19 to the financial statements.

The carrying amounts of cash and cash equivalents, trade and other receivables, other financial assets, trade and other payables and other financial liabilities represents their fair values determined in accordance with the accounting policies disclosed in note 19.

Interest revenue on cash and cash equivalents and foreign exchange movements on trade and other receivables and trade and other payables are disclosed in notes 2 and 3.

For personal use only



## 9 Financial risk management (continued)

### (d) Capital risk management

The Group's objectives when managing capital are to safeguard the Group's ability to continue as a going concern and to maintain an optimal capital structure so as to maximise shareholders' value. In order to maintain or achieve an optimal capital structure, the Group may issue new shares or reduce its capital, subject to the provisions of the Group's constitution. The capital structure of the Group consists of equity attributed to equity holders of the Group, comprising contributed equity, reserves and accumulated losses disclosed in note 7. By monitoring undiscounted cash flow forecasts and actual cash flows provided to the Board by the Group's Management the Board monitors the need to raise additional equity from the equity markets.

### (e) Financial risk management

The main risks the Group is exposed to through its operations are interest rate risk, price risk, foreign exchange risk, credit risk and liquidity risk.

#### (i) Interest rate risk

The Group is exposed to interest rate risks via the cash and cash equivalents that it holds. Interest rate risk is the risk that a financial instruments value will fluctuate as a result of changes in market interest rates.

The objective of managing interest rate risk is to minimise the Group's exposure to fluctuations in interest rate that might impact its interest revenue and cash flow. The Group is exposed to security price risk which is the risk that a change in the value of the equity will impact on the Group's net results or net assets position on investments. Equity investments are held for strategic rather than trading purposes. The Group does not actively trade these investments.

#### (ii) Foreign exchange risk

The Group is exposed to foreign currency risk mainly through its foreign currency cash balances, receivables and payables denominated in foreign currencies, and financial instruments held by overseas operations. The Group's exposures are mainly against the US dollar (USD) and British Pound (GBP) (2016: Euro (EUR)), and are managed through continuous monitoring of movements in exchange rates, and by settling foreign currency purchases with proceeds from foreign currency income. Based on past and current assessment of economic outlook, it is deemed unnecessary for the Group to enter into any hedging arrangements to manage the risk. The Group's sensitivity to foreign currency movements is set out below.

The objective of managing interest rate risk is to minimise the Group's exposure to fluctuations in interest rate that might impact its interest revenue and cash flow. The Group is exposed to security price risk which is the risk that a change in the value of the equity will impact on the Group's net results or net assets position on investments. Equity investments are held for strategic rather than trading purposes. The Group does not actively trade these investments.

#### **The Group holds the following amounts in currencies other than its functional currency (amounts presented in AUD):**

<b>2017</b>	<b>USD</b>	<b>GBP</b>	<b>Total</b>
Cash and cash equivalents	31,405	22,047	53,452
Other financial assets	85,360	42,688	128,048
Other financial liabilities	(86,935)	-	(86,935)
<b>Net financial assets</b>	<b>29,830</b>	<b>64,735</b>	<b>94,565</b>

## 9 Financial risk management (continued)

### (e) Financial risk management (continued)

#### (iii) Credit risk

Exposure to credit risk relating to financial assets arises from the potential non-performance by counterparties of contract obligations that could lead to a financial loss for the Group. The Group has no significant concentration of credit risk with any single counterparty or group of counterparties. Risk is also managed by investing surplus funds in financial institutions that maintain a high credit rating.

The maximum exposure to credit risk by class of financial assets at the end of the reporting period, including the value of any collateral or other security held is equivalent to the carrying value and classification of those financial assets (net of any provision) as presented in the consolidated statement of financial position.

#### (iv) Liquidity risk

Liquidity risk arises from the possibility that the Group might encounter difficulty in settling its debts or otherwise meeting its obligations related to financial liabilities. The Group manages this risk as follows:

- preparation of cashflow analyses related to its operating, investing and financing activities;
- monitoring undrawn credit facility;
- obtaining funding from a variety of sources;
- managing credit risk related to financial assets; and
- investing surplus funds with reputable financial institutions.
- investing surplus funds with reputable financial institutions.<sup>1</sup>

The Group's exposure to interest rate risk and the weighted average interest rates on the Group's financial assets and financial liabilities is as follows:

2017	Note	Floating interest rate \$	Non-interest bearing \$	Fixed interest bearing \$	Total \$
<b>Financial assets</b>					
Cash and cash equivalents*	5(a)	1,666,883	-	-	1,666,883
Other financial assets	5(d)	-	-	51,475	51,475
Trade and other receivables	5(b)	-	514,275	-	514,275
		<u>1,666,883</u>	<u>514,275</u>	<u>51,475</u>	<u>2,232,633</u>
<b>Financial liabilities</b>					
Trade and other payables	5(e)	-	979,615	-	979,615
<b>Net financial assets</b>		<u>1,666,883</u>	<u>(465,340)</u>	<u>51,475</u>	<u>1,253,018</u>

\* Weighted average effective interest rate: 1.85%

For personal use only

**Rhinomed Limited**  
**Note to the consolidated financial statements**  
**30 June 2017**  
(continued)

**9 Financial risk management (continued)**

**(e) Financial risk management (continued)**

(iv) *Liquidity risk (continued)*

**2016**

**Financial assets**

Cash and cash equivalents**	5(a)	2,612,757	-	-	2,612,757
Other financial assets	5(d)	-	-	103,775	103,775
Trade and other receivables	5(b)	-	510,645	-	510,645
		<u>2,612,757</u>	<u>510,645</u>	<u>103,775</u>	<u>3,227,177</u>

**Financial liabilities**

Trade and other payables	5(e)	-	895,818	-	895,818
<b>Net financial assets</b>		<u>2,612,757</u>	<u>(385,173)</u>	<u>103,775</u>	<u>2,331,359</u>

\*\* Weighted average effective interest rate: 1.72%

(v) *Maturity profile*

<b>2017</b>	<b>Note</b>	<b>Carrying amount</b>	<b>Contractual cash flow</b>	<b>Within 1 year</b>	<b>1-5 years</b>	<b>Total</b>
		<b>\$</b>	<b>\$</b>	<b>\$</b>	<b>\$</b>	<b>\$</b>
<b>Financial assets</b>						
Cash and cash equivalents	5(a)	1,666,883	1,666,883	1,666,883	-	1,666,883
Other financial assets	5(d)	51,475	51,475	-	51,475	51,475
Trade and other receivables	5(b)	514,275	514,275	514,275	-	514,275
<b>Total financial assets</b>		<u>2,232,633</u>	<u>2,232,633</u>	<u>2,181,158</u>	<u>51,475</u>	<u>2,232,633</u>
<b>Financial liabilities</b>						
Trade and other payables	5(e)	979,615	979,615	979,615	-	979,615
<b>Total financial liabilities</b>		<u>979,615</u>	<u>979,615</u>	<u>979,615</u>	<u>-</u>	<u>979,615</u>
<b>2016</b>						
<b>Financial assets</b>						
Cash and cash equivalents	5(a)	2,612,757	2,612,757	2,612,757	-	2,612,757
Other financial assets	5(d)	103,775	103,775	-	103,775	103,775
Trade and other receivables	5(b)	510,645	510,645	510,645	-	510,645
<b>Total financial assets</b>		<u>3,227,177</u>	<u>3,227,177</u>	<u>3,123,402</u>	<u>103,775</u>	<u>3,227,177</u>
<b>Financial liabilities</b>						
Trade and other payables	5(e)	895,818	895,818	895,818	-	895,818
<b>Total financial liabilities</b>		<u>895,818</u>	<u>895,818</u>	<u>895,818</u>	<u>-</u>	<u>895,818</u>

(vi) *Net fair values*

The Directors consider that the carrying amount of financial assets and liabilities recorded in the financial statements approximate their fair value.

## 9 Financial risk management (continued)

### (e) Financial risk management (continued)

#### (vii) Sensitivity analysis

The following table illustrates sensitivities to the Group's exposures to change in interest rates and equity prices. The table indicates the impact on how profit and equity values reported at the end of the reporting period would have been affected by changes in the relevant risk variable that management considers to be reasonably possible. These sensitivities assume that the movement in a particular variable is independent of other variables.

2017	Note	Total balance \$	Interest rate risk (±1%) \$	Other price risk (±5%) \$
Cash	5(a)	1,666,883	16,669	-
Other financial assets	5(d)	51,475	-	2,574
<b>Total increase/decrease</b>		<b>1,718,358</b>	<b>16,669</b>	<b>2,574</b>

#### 2016

Cash	5(a)	2,612,757	26,128	-
Other financial assets	5(d)	103,775	-	5,189
<b>Total increase/decrease</b>		<b>2,716,532</b>	<b>26,128</b>	<b>5,189</b>

2017	AUD/USD (±5%) \$	AUD/GBP (±5%) \$
Net financial assets/(liabilities)	1,491	3,237
<b>Total increase/decrease</b>	<b>1,491</b>	<b>3,237</b>

2016	AUD/USD (±5%) \$	AUD/EUR (±5%) \$
Net financial assets/(liabilities)	107	6,082
<b>Total increase/decrease</b>	<b>107</b>	<b>6,082</b>

### (f) Financial instruments measured at fair value

The financial instruments recognised at fair value in the statement of financial position have been analysed and classified using a fair value hierarchy reflecting the significance of the inputs used in making the measurements. The fair value hierarchy consists of the following levels:

- quoted prices in active markets for identical assets or liabilities (Level 1);

For personal use only

## 9 Financial risk management (continued)

### (f) Financial instruments measured at fair value (continued)

- inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (as prices); or
- indirectly (derived from prices) (Level 2); and
- inputs for the asset or liability that are not based on observable market data (unobservable inputs) (Level 3).

In 2017 and 2016, none of the Group's assets and liabilities except for the other financial assets had their fair value determined using the fair value hierarchy. The other financial assets are classified as level 1 instruments. No transfers between the levels of the fair value hierarchy occurred during the current or previous years.

## 10 Contingent liabilities and contingent assets

There are no known significant liabilities or contingent assets as at the date of this report, other than those disclosed in this financial report.

## 11 Commitments

### (a) Non-cancellable operating leases

	<b>Consolidated entity</b>	
	<b>2017</b>	<b>2016</b>
	\$	\$
<b>Commitments for minimum lease payments in relation to non-cancellable operating leases are payable as follows:</b>		
Within one year	<b>95,950</b>	67,825
Later than one year but not later than five years	<b>173,238</b>	-
	<b>269,188</b>	<b>67,825</b>

The property lease is a non-cancellable lease with a 3 year term, with rent payable monthly in advance. Contingent rental provisions within the lease agreement require the minimum lease payments shall be increased by 4% per annum. The current lease expires on the 31 March 2020. An option exists to renew the lease at the end of the 3 year term for an additional term of 3 years.

### (b) Other expenditure commitments

	<b>Consolidated entity</b>	
	<b>2017</b>	<b>2016</b>
	\$	\$
<b>Commitments contracted for at balance date but not recognised as liabilities are as follows:</b>		
Within one year	<b>3,678</b>	2,759
Later than one year but not later than five years	-	3,678
	<b>3,678</b>	<b>6,437</b>

## 12 Events occurring after the reporting period

The Directors are not aware of any significant events since the end of the reporting period.

For personal use only

### 13 Related party transactions

#### (a) Parent entities

Rhinomed Limited is the parent entity.

#### (b) Subsidiaries

Interests in subsidiaries are set out in note 18.

#### (c) Key management personnel

Disclosures relating to key management personnel are set out in the remuneration report in the Directors' report.

##### (i) Details of key management personal

###### Directors:

- Michael Johnson - Executive Director
- Eric Knight - Non-Executive Director
- Ron Dewhurst - Non-Executive Chairman
- Brent Scrimshaw - Non-Executive Director

###### Executives:

- Justine Heath - Chief Financial Officer and Chief Operating Officer
- Shane Duncan - Vice President Sales and Marketing

##### (ii) Compensation

The aggregate compensation made to Directors and other members of key management personnel of the consolidated entity is set out below:

	<b>Consolidated entity</b>	
	<b>2017</b>	<b>2016</b>
	\$	\$
Short-term employee benefits	716,650	850,239
Post-employment benefits	42,911	53,056
Share-based payments	<b>633,000</b>	118,000
	<b>1,392,561</b>	1,021,295

##### (iii) Other related party transactions

	<b>Consolidated entity</b>	
	<b>2017</b>	<b>2016</b>
	\$	\$
<b>Payment for goods and services</b>		
Smart Street*	<b>96,400</b>	50,572

\* Consulting fees paid to Smart Street, Director related entity to Mr Michael Johnston.

##### (iv) Receivable from and payable to related parties

Balance outstanding at the end of the current year to Smart Street is \$9,540 (2016: \$5,968). There are no other outstanding balances at the reporting date in relation to transactions with related parties.

For personal use only

**Rhinomed Limited**  
**Note to the consolidated financial statements**  
**30 June 2017**  
(continued)

**13 Related party transactions (continued)**

**(c) Key management personnel (continued)**

(v) *Loans to/from related parties*

All transactions were made on normal commercial terms and conditions and at market rates.

(vi) *Terms and conditions*

There were no loans to or from related parties at the current and previous reporting date.

**14 Share-based payments**

Set out below are summaries of options granted under the employee share option plan which was established to provide ongoing incentive to reward employees and consultants for their contribution to the Group's performance:

**2017**

Grant date	Expiry date	Exercise price \$	Balance at 1 July	Granted	Exercised, other	Expired, forfeited	Consolidation 10:1	Balance at 30 June*
27/05/2013	30/04/2017	0.060	95,400,000	-	-	(95,400,000)	-	-
18/11/2013	30/04/2017	0.060	15,250,000	-	-	(15,250,000)	-	-
11/04/2014	30/04/2017	0.060	2,500,000	-	-	(2,500,000)	-	-
11/04/2014	30/04/2017	0.065	40,000,000	-	-	(40,000,000)	-	-
23/09/2015	30/07/2017	0.600	90,000,000	-	-	(90,000,000)	-	-
23/12/2015	30/04/2019	0.650*	769,230	-	-	-	76,923	76,923
11/04/2016	11/04/2019	0.650*	18,000,000	-	-	-	1,800,000	1,800,000
20/05/2016	30/04/2019	0.670*	10,000,000	-	-	-	1,000,000	1,000,000
24/01/2017	30/12/2020	0.400	-	150,000	-	-	-	150,000
28/04/2017	30/04/2020	0.270	-	6,000,000	-	-	-	6,000,000
			<b>271,919,230</b>	<b>6,150,000</b>	<b>-</b>	<b>(243,150,000)</b>	<b>2,876,923</b>	<b>9,026,923</b>
<b>Weighted average exercise price:</b>			<b>\$0.064</b>	<b>\$0.335</b>	<b>\$0.00</b>	<b>\$0.061</b>		<b>\$0.528*</b>

\*On 3 May 2017 the share capital of the Company has been consolidated through the conversion to one share for every ten shares held.

**2016**

Grant date	Expiry date	Exercise price \$	Balance at 1 July	Granted	Exercised, other	Expired, forfeited	Consolidation 10:1	Balance at 30 June
13/07/2012	31/07/2015	0.120	2,000,000	-	-	(2,000,000)	-	-
27/05/2013	30/04/2017	0.060	95,400,000	-	-	-	-	95,400,000
18/11/2013	30/04/2017	0.060	15,250,000	-	-	-	-	15,250,000
11/04/2014	30/04/2017	0.060	2,500,000	-	-	-	-	2,500,000
11/04/2014	30/04/2017	0.065	40,000,000	-	-	-	-	40,000,000
23/09/2015	30/07/2017	0.600	-	90,000,000	-	-	-	90,000,000
23/12/2015	30/04/2019	0.065	-	769,230	-	-	-	769,230
11/04/2016	11/04/2019	0.065	-	18,000,000	-	-	-	18,000,000
20/05/2016	30/04/2019	0.067	-	10,000,000	-	-	-	10,000,000
			<b>97,400,000</b>	<b>108,769,230</b>	<b>-</b>	<b>(2,000,000)</b>	<b>-</b>	<b>271,919,230</b>
<b>Weighted average exercise price:</b>			<b>\$0.062</b>	<b>\$0.066</b>	<b>\$0.00</b>	<b>\$0.120</b>		<b>\$0.064</b>

For personal use only

**Rhinomed Limited**  
**Note to the consolidated financial statements**  
**30 June 2017**  
(continued)

**14 Share-based payments (continued)**

Set out below are the options issued under the employee share option plan that are exercisable at the end of the financial year:

Grant date	Expiry date	Number of options (2017)	Number of options (2016)
27/05/2013	30/04/2017	-	95,400,000
18/11/2013	30/04/2017	-	15,250,000
11/04/2014	30/04/2017	-	2,500,000
11/04/2014	30/04/2017	-	40,000,000
03/04/2013	30/04/2017	-	90,000,000
23/12/2015	30/04/2019	76,923	769,230
11/04/2016	11/04/2019	1,800,000	18,000,000
20/05/2016	30/04/2019	1,000,000	10,000,000
24/01/2017	30/12/2020	150,000	-
28/04/2017	30/04/2020	6,000,000	-
<b>Total exercisable</b>		<b>9,026,923</b>	<b>271,919,230</b>

The weighted average remaining contractual life of options outstanding at year end is 2.36 years (2016: 1.57 years).

Refer to note 7 for details of options issued during the year to key management personnel as share based payments.

**15 Remuneration of auditors**

During the year the following fees were paid or payable for services provided by HLB Mann Judd, the auditor of the Group.

**(a) HLB Mann Judd**

*(i) Audit and other assurance services*

	Consolidated entity	
	2017	2016
	\$	\$
<i>Audit services</i>		
Audit or review of the financial statements	<b>54,000</b>	41,000
	<b>54,000</b>	41,000

*(ii) Other services*

<i>Other services</i>		
Preparation of tax returns	<b>12,500</b>	12,611
Due diligence	<b>20,000</b>	-
	<b>32,500</b>	12,611

<b>Total remuneration of HLB Mann Judd</b>	<b>86,500</b>	<b>53,611</b>
--	---------------	---------------

For personal use only



**Rhinomed Limited**  
**Note to the consolidated financial statements**  
**30 June 2017**  
(continued)

**16 Earnings per share**

**(a) Reconciliation of earnings used in calculating earnings per share**

	<b>Consolidated entity</b>	
	<b>2017</b>	<b>2016</b>
	<b>\$</b>	<b>\$</b>
<b>Loss attributable to parent entity</b>		
Loss	(4,441,578)	(5,998,529)
Loss attributable to non-controlling interest	-	-
	(4,441,578)	(5,998,529)
<i>Basic earnings per share</i>		
Profit attributable to the ordinary equity holders of the Group used in calculating basic earnings per share:		
From continuing operations	(6.61)	(9.43)
Weighted average number of ordinary shares outstanding during the year used to calculate basic and diluted EPS	67,223,730	63,638,911

\*Basic and diluted loss per share for the prior financial year have been restated to align with current year's amount based on post consolidation of one share for every ten shares held.

**17 Parent entity financial information**

**(a) Summary financial information**

Set out below is the supplementary information about the parent entity.

	<b>2017</b>	<b>2016</b>
	<b>\$</b>	<b>\$</b>
<b>Balance sheet</b>		
Current assets	1,567,282	13,785,032
Non-current assets	32,942,473	20,367,028
<b>Total assets</b>	34,509,755	34,152,060
Current liabilities	389,724	316,865
Non-current liabilities	7,620	-
<b>Total liabilities</b>	397,344	316,865
<b>Net assets</b>	34,112,411	33,835,195
<i>Shareholders' equity</i>		
Issued capital	50,934,839	48,919,157
Other reserves	997,688	3,803,218
Retained earnings	(17,820,116)	(18,887,178)
<b>Total equity</b>	34,112,411	33,835,197
<b>Profit/(loss) for the year</b>	(2,386,002)	(2,062,102)
<b>Total comprehensive income/(loss) for the year</b>	(2,386,002)	(2,062,102)

For personal use only

## 17 Parent entity financial information (continued)

### (a) Summary financial information (continued)

### (b) Guarantees entered into by the parent entity

The parent entity has not entered into any guarantees in the current or prior financial year in relation to debts of its subsidiaries.

### (c) Contingent liabilities of the parent entity

Refer to note 10 for details.

### (d) Contract commitments

Refer to note 11 for details.

### (e) Significant accounting policies

The accounting policies of the parent entity are consistent with those of the consolidated entity, as disclosed in note 19.

## 18 Subsidiaries

The consolidated financial statements include the financial statements of the Group and the following subsidiaries:

Subsidiary	Country of incorporation	2017 %	2016 %
Helicon (Asia) Pty Ltd	Australia	100	100
Helicon (China) Pty Ltd	Australia	100	100
Helicon (Korea) Pty Ltd	Australia	100	100
Helicon International Limited	Australia	100	100
Leading Edge Instruments Pty Ltd (LEI)	Australia	100	100
Breathing Space Health Pty Ltd	Australia	100	100
<i>Subsidiaries of LEI:</i>			
• Vibrovein Pty Ltd	Australia	100	100
• ASAP Breatheassist Pty Ltd	Australia	100	100
Rhinomed UK Limited*	United Kingdom	100	100
Breatheassist Limited	United Kingdom	100	100
Rhinomed Inc.**	United States	100	-

\* formally known as Consegna Management Services Limited.

\*\* Rhinomed Inc. is a newly formed entity set up to commercialise operations in the United States.

All shares held in subsidiaries represent ordinary shares and the voting rights are equal to the ownership percentage.

There are no significant restrictions over the Group's ability to access or use assets and settle liabilities of the Group.

On 16 August 2017, the following dormant fully owned subsidiaries within the Group have been de-registered:

- Helicon (Asia) Pty Ltd
- Helicon (China) Pty Ltd
- Helicon (Korea) Pty Ltd
- Helicon International Pty Ltd (Formerly Helicon International Limited)
- Leading Edge Instruments Pty Ltd (Formerly Leading Edge Instruments Limited)
- Vibrovein Pty Ltd

For personal use only

## 19 Summary of significant accounting policies

### (a) Corporate information

The financial report of Rhinomed Limited and its subsidiaries (the "Consolidated Entity" or "Group") for the year ended 30 June 2017 was authorised for issue in accordance with a resolution of the Directors on the 29th day of September 2017. The financial report is for the Group consisting of Rhinomed Limited and its subsidiaries.

Rhinomed Limited is a listed public company limited by shares incorporated and domiciled in Australia whose shares are publicly traded on the Australian Securities Exchange. The principal activity of the Group is the research, development and commercialisation of consumer and medical devices.

### (b) Basis of preparation

The financial report is a general-purpose financial report, which has been prepared in accordance with the requirements of the *Corporations Act 2001* and Australian Accounting Standards, required for a for-profit entity.

Except for cash flow information, the financial statements have been prepared on an accruals basis and are based on historical costs, modified, where applicable, by the measurement at fair value of selected financial assets and financial liabilities. The financial report is presented in Australian dollars, which is the Group's functional and presentation currency. All values are rounded to the nearest dollar unless otherwise stated.

Management is required to make judgements, estimates and assumptions about carrying values of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and various other factors that are believed to be reasonable under the circumstance, the results of which form the basis of making the judgements. Actual results may differ from these estimates. The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised if the revision affects only that period, or in the period of the revision and future periods if the revision affects both current and future periods.

Judgements made by management in the application of Australian Accounting Standards that have significant effects on the financial statements and estimates with a significant risk of material adjustments in the next year are disclosed, where applicable, in the relevant notes to the financial statements.

Accounting policies are selected and applied in a manner which ensures that the resulting financial information satisfies the concepts of relevance and reliability, thereby ensuring that the substance of the underlying transactions or other events is reported.

#### (i) Going concern

At 30 June 2017, the Group's cash and cash equivalents amounted to \$1,666,883 (2016: \$2,612,757) and for the year ended 30 June 2017, the Group experienced a loss of \$4,441,578 (2016: \$5,998,529) and a net cash outflow from operating activities of \$2,996,256 (2016: net cash outflow of \$6,125,015).

Based on current budget assumptions the Group has sufficient funds to meet current commitments towards commercialising the BreatheAssist asset in the sporting and health market.

There are significant risks associated with product development and regulatory approvals required by biotechnology companies, as such it is difficult to predict the exact timing and quantum of income from the commercialisation of products and technology and there are inherent uncertainties involved in raising funds from investors within forecasted timelines.

As a result of these matters, there is material uncertainty that may cast significant doubt as to whether the Group will be able to continue as a going concern and realise its assets and discharge its liabilities in the normal course of business and at the amounts stated in the financial report.

## 19 Summary of significant accounting policies (continued)

### (b) Basis of preparation (continued)

#### (i) Going concern (continued)

Notwithstanding the material uncertainty pertaining to the ability of the Group to continue to access additional capital and its future operating income, the financial statements have been prepared on a going concern basis. Accordingly the financial statements do not include adjustments relating to the recoverability and classification of recorded asset amounts, or the amounts and classification of liabilities that might be necessary should the Group not continue as a going concern.

#### (ii) Statement of compliance

The financial report complies with Australian Accounting Standards as issued by the Australian Accounting Standards Board and International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board.

#### (iii) New accounting standards and interpretations

The following amending Standards have been adopted from 1 July 2016. Adoption of these Standards did not have any effect on the financial position or performance of the Group:

Title	Nature of change
AASB 2014-3 <i>Amendments to Australian Accounting Standards - Accounting for Acquisitions of Interests in Joint Operations</i>	<p>The amendments to AASB 11 state that an acquirer of an interest in a joint operation in which the activity of the joint operation constitutes a 'business', as defined in AASB 3 Business Combinations, should:</p> <ol style="list-style-type: none"> <li>1. Apply all of the principles on business combinations accounting in AASB 3 and other Australian Accounting Standards except principles that conflict with the guidance of AASB 11. This requirement also applies to the acquisition of additional interests in an existing joint operation that results in the acquirer retaining joint control of the joint operation (note that this requirement applies to the additional interest only, i.e. the existing interest is not re-measured) and to the formation of a joint operation when an existing business is contributed to the joint operation by one of the parties that participate in the joint operation; and</li> <li>2. Provide disclosures for business combinations as required by AASB 3 and other Australian Accounting Standards.</li> </ol> <p>Impact: The adoption of this amendment has not had a material impact on the Company.</p> <p>Application date: AASB 2015-4 is applicable to annual reporting periods beginning on or after 1 July 2016.</p>
AASB 2014-4 <i>Amendments to Australian Accounting Standards - Clarification of Acceptable Methods of Depreciation and Amortisation</i>	<p>The amendments to AASB 116 prohibit the use of a revenue based depreciation method for property, plant and equipment. Additionally, the amendments provide guidance in the application of the diminishing balance method for property, plant and equipment. The amendments to AASB 138 present a rebuttable presumption that a revenue-based amortisation method for intangible assets is inappropriate. This rebuttable presumption can be overcome (i.e. a revenue-based amortisation method might be appropriate) only in two (2) limited circumstances:</p> <ol style="list-style-type: none"> <li>1. The intangible asset is expressed as a measure of revenue, for example when the predominant limiting factor inherent in an intangible asset is the achievement of a revenue threshold (for instance, the right to operate a toll road could be based on a fixed total amount of revenue to be generated from cumulative tolls charged); or</li> <li>2. When it can be demonstrated that revenue and the consumption of the economic benefits of the intangible asset are highly correlated.</li> </ol> <p>Impact: The adoption of this amendment has not had a material impact on the Company.</p> <p>Application date: AASB 2015-4 is applicable to annual reporting periods beginning on or after 1 July 2016.</p>

For personal use only

**19 Summary of significant accounting policies (continued)**

**(b) Basis of preparation (continued)**

*(iii) New accounting standards and interpretations (continued)*

<b>Title</b>	<b>Nature of change</b>
AASB 2014-9 <i>Amendments to Australian Accounting Standards - Equity Method in Separate Financial Statements</i>	The amendments introduce the equity method of accounting as one of the options to account for an entity's investments in subsidiaries, joint ventures and associates in the entity's separate financial statements.  Impact: The adoption of this amendment has not had a material impact on the Company.  Application date: AASB 2015-4 is applicable to annual reporting periods beginning on or after 1 July 2016.
<i>Standards - Disclosure Initiative: Amendments to AASB 101</i>	Disclosure Initiative project. The amendments: <ul style="list-style-type: none"> <li>• clarify the materiality requirements in AASB 101, including an emphasis on the potentially detrimental effect of obscuring useful information with immaterial information</li> <li>• clarify that AASB 101's specified line items in the statement(s) of profit or loss and other comprehensive income and the statement of financial position can be disaggregated</li> <li>• add requirements for how an entity should present subtotals in the statement(s) of profit and loss and other comprehensive income and the statement of financial position</li> <li>• clarify that entities have flexibility as to the order in which they present the notes, but also emphasise that understandability and comparability should be considered by an entity when deciding that order</li> <li>• remove potentially unhelpful guidance in AASB 101 for identifying a significant accounting policy</li> </ul> Application date: Standards - Disclosure Initiative: Amendments to AASB 101 is applicable to annual reporting periods beginning on or after 1 July 2016.

Other than the amended accounting standards listed above, all other accounting standards adopted by the Group are consistent with the most recent Annual Report for the year ended 30 June 2017.

*(iv) New standards and interpretations not yet adopted*

The following Australian Accounting Standards and Interpretations have recently been issued or amended but are not yet effective and therefore have not been adopted by the Group for the financial year ended 30 June 2017:

<b>Title</b>	<b>Nature of change</b>	<b>Impact</b>	<b>Application date</b>
AASB 15 <i>Revenue from Contracts with Customers</i>	AASB 15 <ul style="list-style-type: none"> <li>– replaces AASB 118 Revenue, AASB 111 Construction Contracts and some revenue-related Interpretations</li> <li>– establishes a new revenue recognition model</li> <li>– changes the basis for deciding whether revenue is to be recognised over time or at a point in time</li> <li>– provides new and more detailed guidance on specific topics (e.g. multiple element arrangements, variable pricing, rights of return, warranties and licensing)</li> <li>– expands and improves disclosures about revenue</li> </ul>	Although the Directors anticipate that the adoption of AASB 15 will have an impact on the Group's financial statements, it is impracticable at this stage to provide a reasonable estimate of such impact.	Must be applied for financial years commencing on or after 1 January 2018.

For personal use only

**19 Summary of significant accounting policies (continued)**

**(b) Basis of preparation (continued)**

*(iv) New standards and interpretations not yet adopted (continued)*

Title	Nature of change	Impact	Application date
AASB 9 <i>Financial Instruments</i>	<p>AASB 9 introduces new requirements for the classification and measurement of financial assets and liabilities and includes a forward- looking 'expected loss' impairment model and a substantially-changed approach to hedge accounting. These requirements improve and simplify the approach for classification and measurement of financial assets compared with the requirements of AASB 139. The main changes are:</p> <p>A. Financial assets that are debt instruments will be classified based on: (i) the objective of the entity's business model for managing the financial assets; and (ii) the characteristics of the contractual cash flows.</p> <p>B. Allows an irrevocable election on initial recognition to present gains and losses on investments in equity instruments that are not held for trading in other comprehensive income (instead of in profit or loss). Dividends in respect of these investments that are a return on investment can be recognised in profit or loss and there is no impairment or recycling on disposal of the instrument.</p> <p>C. Introduces a 'fair value through other comprehensive income' measurement category for particular simple debt instruments.</p> <p>D. Financial assets can be designated and measured at fair value through profit or loss at initial recognition if doing so eliminates or significantly reduces a measurement or recognition inconsistency that would arise from measuring assets or liabilities, or recognising the gains and losses on them, on different bases.</p> <p>E. Where the fair value option is used for financial liabilities the change in fair value is to be accounted for as follows:</p> <ul style="list-style-type: none"> <li>• the change attributable to changes in credit risk are presented in Other Comprehensive Income (OCI)</li> <li>• the remaining change is presented in profit or loss. If this approach creates or enlarges an accounting mismatch in the profit or loss, the effect of the changes in credit risk are also presented in profit or loss.</li> </ul> <p>Otherwise, the following requirements have generally been carried forward unchanged from AASB 139 into AASB 9:</p> <ul style="list-style-type: none"> <li>• classification and measurement of financial liabilities; and</li> <li>• derecognition requirements for financial assets and liabilities</li> </ul> <p>AASB 9 requirements regarding hedge accounting represent a substantial overhaul of hedge accounting that enable entities to better reflect their risk management activities in the financial statements. Furthermore, AASB 9 introduces a new impairment model based on expected credit losses. This model makes use of more forward-looking information and applies to all financial instruments that are subject to impairment accounting.</p>	The Group is still determining if there will be any potential impact.	Must be applied for financial years commencing on or after 1 January 2018.

For personal use only

## 19 Summary of significant accounting policies (continued)

### (b) Basis of preparation (continued)

(iv) *New standards and interpretations not yet adopted (continued)*

Title	Nature of change	Impact	Application date
AASB 16 <i>Leases</i>	AASB 16 <ul style="list-style-type: none"> <li>– replaces AASB 117 Leases and some lease-related Interpretations</li> <li>– requires all leases to be accounted for ‘on-balance sheet’ by lessees, other than short-term and low value asset leases</li> <li>– provides new guidance on the application of the definition of lease and on sale and lease back accounting</li> <li>– largely retains the existing lessor accounting requirements in AASB 117</li> <li>– requires new and different disclosures about leases</li> </ul>	Whilst the impact of AASB 16 has not yet been quantified, the entity currently has \$103,808 worth of operating leases which we anticipate will be brought onto the statement of financial position. Interest and amortisation expense will increase and rental expense will decrease.	Must be applied for financial years commencing on or after 1 January 2019.
AASB 2016-1 <i>Amendments to Australian Accounting Standards - Recognition of Deferred Tax Assets for Unrealised Losses</i>	AASB 2016-1 amends AASB 112 Income Taxes to clarify how to account for deferred tax assets related to debt instruments measured at fair value, particularly where changes in the market interest rate decrease the fair value of a debt instrument below cost.	No impact	Must be applied for financial years commencing on or after 1 January 2017.
AASB 2016-2 <i>Amendments to Australian Accounting Standards - Disclosure Initiative: Amendments to AASB 107</i>	AASB 2016-2 amends AASB 107 Statement of Cash Flows to require entities preparing financial statements in accordance with Tier 1 reporting requirements to provide disclosures that enable users of financial statements to evaluate change in liabilities arising from financing activities, including both changes arising from cash flows and non-cash changes.	No impact	Must be applied for financial years commencing on or after 1 January 2017.

### (c) Accounting policies

The following is a summary of the material accounting policies adopted by the Group in the preparation of the financial report. The accounting policies have been consistently applied, unless otherwise stated.

### (d) Principles of consolidation

The consolidated financial statements incorporate the assets and liabilities of all subsidiaries of Rhinomed Limited as at 30 June 2017 and the results of all subsidiaries for the year then ended.

For personal use only

## **19 Summary of significant accounting policies (continued)**

### **(d) Principles of consolidation (continued)**

Subsidiaries are entities the parent controls. The parent controls an entity when it is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power over the entity. A list of the subsidiaries is provided in note 18.

Subsidiaries are fully consolidated from the date on which control is transferred to the Group. They are de-consolidated from the date that control ceases.

In preparing the consolidated financial statements, all intercompany balances and transactions, and unrealised profits/losses arising within the consolidated entity are eliminated in full. Investments in subsidiaries are accounted for at cost in the individual financial statements of Rhinomed Limited.

### **(e) Revenue recognition**

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Group and the revenue can be reliably measured. The following specific recognition criteria must also be met before revenue is recognised.

Revenue from the sale of goods is recognised at the point of delivery as this corresponds to the transfer of significant risks and rewards of ownership of the goods and the cessation of all involvement in those goods.

Interest revenue is recognised when control of the right to receive the interest payment is obtained and measured using the effective interest rate method.

### **(f) Government grants**

Government grants are recognised when there is reasonable assurance that the grant will be received and all grant conditions will be complied with.

When the grant relates to an expense item, it is recognised as income over the periods necessary to match the grant on a systematic basis to the costs that it is expected to compensate.

### **(g) Borrowing costs**

Borrowing costs are expensed as incurred unless they relate to the construction of qualifying assets in which case they are capitalised.

### **(h) Leases**

The minimum lease payments of operating leases, where the lessor effectively retains substantially all of the risks and benefits of ownership of the leased item, are recognised as an expense on a straight-line basis.

### **(i) Cash and cash equivalents**

Cash and short-term deposits in the consolidated statement of financial position comprise cash at bank and in hand and short-term deposits with an original maturity of three months or less.

For the purposes of the consolidated statement of cash flows, cash and cash equivalents consist of cash and cash equivalents as defined above.

### **(j) Trade and other receivables**

Trade and other receivables are recognised initially at fair value and subsequently measured at amortised cost using the effective interest method, less an allowance for impairment. A separate account records the impairment.

For personal use only



## **19 Summary of significant accounting policies (continued)**

### **(j) Trade and other receivables (continued)**

An allowance for impairment is made when there is objective evidence that the Group will not be able to collect the debts. The criteria used to determine that there is objective evidence that an impairment loss has occurred include whether the Financial Asset is past due and whether there is any other information regarding increased credit risk associated with the Financial Asset. Bad debts which are known to be uncollectible are written off when identified.

When the terms of financial assets that would otherwise have been past due or impaired have been renegotiated, the Group recognises the impairment for such financial assets by taking into account the original terms as if the terms have not been renegotiated so that the loss events that have occurred are duly considered.

### **(k) Inventories**

Raw materials, work in progress and finished goods are stated at the lower of cost and net realisable value on a weighted average cost basis. Cost comprises direct materials and delivery costs, direct labour, import duties and other taxes. Costs of purchased inventory are determined after deducting rebates and discounts received or receivable.

### **(l) Foreign currency translation**

The functional currency of the Group is based on the primary economic environment in which the Group operates. The functional currency of the Group is Australia dollars. Transactions in foreign currencies are converted to local currency at the rate of exchange at the date of the transaction.

Amounts payable to and by the Group outstanding at reporting date and denominated in foreign currencies have been converted to local currency using rates prevailing at the end of the financial year.

Exchange differences arising on the translation of monetary items are recognised in profit or loss. Exchange differences arising on the translation of non-monetary items are recognised directly in other comprehensive income to the extent that the underlying gain or loss is recognised in other comprehensive income; otherwise the exchange difference is recognised in profit or loss.

Exchange differences arising on translation of foreign operations with functional currencies other than Australian dollars are recognised in other comprehensive income and included in the foreign currency translation reserve in the statement of financial position. The cumulative amount of these differences is reclassified into profit or loss in the period in which the operation is disposed of.

### **(m) Income tax**

Deferred income tax is provided on all temporary differences at the balance date between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes.

Except for business combinations, no deferred income tax is recognised from the initial recognition of an asset or liability where there is no effect on accounting or taxable profit or loss.

Deferred tax assets and liabilities are calculated at the tax rates that are expected to apply to the period when the asset is realised or the liability is settled and their measurement also reflects the manner in which management expects to recover or settle the carrying amount of the related asset or liability. With respect to non-depreciable items of property, plant and equipment measured at fair value and items of investment property measured at fair value, the related deferred tax liability or deferred tax asset is measured on the basis that the carrying amount of the asset will be recovered entirely through sale.

Deferred tax assets relating to temporary differences and unused tax losses are recognised only to the extent that it is probable that future taxable profit will be available against which the benefits of the deferred tax asset can be utilised.

For personal use only

## **19 Summary of significant accounting policies (continued)**

### **(m) Income tax (continued)**

Where temporary differences exist in relation to investments in subsidiaries, branches, associates and joint ventures, deferred tax assets and liabilities are not recognised where the timing of the reversal of the temporary difference can be controlled and it is not probable that the reversal will occur in the foreseeable future.

Current tax assets and liabilities are offset where a legally enforceable right of set-off exists and it is intended that net settlement or simultaneous realisation and settlement of the respective asset and liability will occur.

Deferred tax assets and liabilities are offset where: (a) a legally enforceable right of set-off exists; and (b) the deferred tax assets and liabilities relate to income taxes levied by the same taxation authority on either the same taxable entity or different taxable entities where it is intended that net settlement or simultaneous realisation and settlement of the respective asset and liability will occur in future periods in which significant amounts of deferred tax assets or liabilities are expected to be recovered or settled.

The carrying amount of deferred income tax assets is reviewed at each balance date and reduced to the extent that it is no longer probable that sufficient taxable profit will be available to allow all or part of the deferred income tax asset to be utilised.

Income taxes relating to items recognised directly in equity are recognised in equity and not in profit or loss.

#### *(i) Tax consolidation*

Rhinomed Limited and all its wholly-owned Australian controlled entities are part of a tax consolidated group under Australian taxation law. Rhinomed Limited is the head entity in the tax-consolidated group.

Rhinomed Limited and the controlled entities in the tax consolidated group account for their own current and deferred tax amounts. These tax amounts are measured as if each entity in the tax consolidated group continues to be a standalone taxpayer in its own right.

In addition to its own current and deferred tax amounts, Rhinomed Limited also recognises the current tax liabilities (or assets) and the deferred tax assets arising from unused tax losses and unused tax credits assumed from controlled entities in the tax consolidated group.

### **(n) Goods and Services Tax (GST)**

Revenues, expenses and assets are recognised net of the amount of GST, except:

- where the GST incurred on a purchase of goods and services is not recoverable from the taxation authority, in which case the GST is recognised as part of the cost of acquisition of the asset or as part of the expense item as applicable; and
- receivables and payables are stated with the amount of GST included.

Cash flows arising from operating activities are included in the consolidated statement of cash flows on a gross basis (i.e. including GST) and the GST component of cash flows arising from investing and financing activities, which is recoverable from, or payable to, the taxation authority are classified as operating cash flows.

Commitments and contingencies are disclosed net of the amount of GST recoverable from, or payable to, the taxation authority. The net amount of GST recoverable from or payable to, the taxation authority is included as part of the receivables or payables in the consolidated statement of financial position.

### **(o) Plant and equipment**

Plant and equipment is measured on the cost basis and therefore carried at cost less accumulated depreciation and any accumulated impairment. In the event the carrying amount of plant and equipment is greater than the estimated recoverable amount, the carrying amount is written down immediately to the estimated recoverable amount and impairment losses are recognised either in profit or loss or as a revaluation decrease if the impairment losses relate to a revalued asset. A formal assessment of recoverable amount is made when impairment indicators are present.

For personal use only

## **19 Summary of significant accounting policies (continued)**

### **(o) Plant and equipment (continued)**

The carrying amount of plant and equipment is reviewed annually by directors to ensure it is not in excess of the recoverable amount from these assets. The recoverable amount is assessed on the basis of the expected net cash flows that will be received from the asset's employment and subsequent disposal. The expected net cash flows have been discounted to their present values in determining recoverable amounts.

Subsequent costs are included in the asset's carrying amount or recognised as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the Group and the cost of the item can be measured reliably. All other repairs and maintenance are charged to the profit or loss during the financial period in which they are incurred.

### **(p) Depreciation**

The depreciable amount of all fixed assets is depreciated on a straight-line basis over the asset's useful life to the consolidated entity commencing from the time the asset is held ready for use. The depreciation rates used are 10 percent to 33 percent for office equipment, and 50 percent for production plant. There have been no changes to depreciation rates or methods since the prior year.

The assets' residual values and useful lives are reviewed, and adjusted if appropriate, at the end of each reporting period. An asset's carrying amount is written down immediately to its recoverable amount if the asset's carrying amount is greater than its estimated recoverable amount.

Gains and losses on disposals are determined by comparing proceeds with the carrying amount. These gains and losses are included in the statement of comprehensive income.

### **(q) Financial assets**

Financial assets in the scope of AASB 139 *Financial Instruments: Recognition and Measurement* are classified as either financial assets at fair value through profit or loss, loans and receivables, held-to-maturity investments, or available-for-sale investments, as appropriate. When financial assets are recognised initially, they are measured at fair value plus, in the case of investments not at fair value through profit or loss, directly attributable transaction costs. The Group determines the classification of its financial assets after initial recognition and, when allowed and appropriate, re-evaluates this designation at each financial year-end. All regular way purchases and sales of financial assets are recognised on the trade date i.e. the date that the Group commits to purchase the asset. Regular way purchases or sales are purchases or sales of financial assets under contracts that require delivery of the assets within the period established generally by regulation or convention in the marketplace.

### **(r) Financial assets at fair value through profit or loss**

Financial assets classified as held for trading are included in the category 'financial assets at fair value through profit or loss'. Financial assets are classified as held for trading if they are acquired for the purpose of selling in the near term. Derivatives are also classified as held for trading unless they are designated as effective hedging instruments. Gains or losses on investments held for trading are recognised in profit or loss.

### **(s) Held-to-maturity investments**

Non-derivative financial assets with fixed or determinable payments and fixed maturity are classified as held-to-maturity when the Group has the positive intention and ability to hold to maturity. Investments intended to be held for an undefined period are not included in this classification. Investments that are intended to be held-to-maturity, such as bonds, are subsequently measured at amortised cost. This cost is computed as the amount initially recognised minus principal repayments, plus or minus the cumulative amortisation using the effective interest method of any difference between the initially recognised amount and the maturity amount. This calculation includes all fees and points paid or received between parties to the contract that are an integral part of the effective interest rate, transaction costs and all other premiums and discounts. For investments carried at amortised cost, gains and losses are recognised in profit or loss when the investments are derecognised or impaired, as well as through the amortisation process.

For personal use only

## **19 Summary of significant accounting policies (continued)**

### **(s) Held-to-maturity investments (continued)**

If the Group were to sell other than an insignificant amount of held-to-maturity financial assets, the whole category would be tainted and reclassified as available-for-sale.

### **(t) Loans and receivables**

Loans and receivables are non-derivative financial assets with fixed or determinable payments that are not quoted in an active market. Such assets are carried at amortised cost using the effective interest method. Gains and losses are recognised in profit or loss when the loans and receivables are derecognised or impaired, as well as through the amortisation process.

### **(u) Impairment of financial assets**

At the end of each reporting period, the Group assesses whether there is objective evidence that a financial instrument has been impaired. A financial asset or group of financial assets is deemed to be impaired if and only if, there is objective evidence of impairment as a result of one or more events (a "loss event") having occurred, which has an impact on the estimated future cash flows of the financial asset(s).

In the case of available-for-sale financial assets, a significant or prolonged decline in the market value of the instrument is considered to constitute a loss event. Impairment losses are recognised in profit or loss immediately. Also, any cumulative decline in fair value previously recognised in other comprehensive income is reclassified into profit or loss at this point.

### **(v) Impairment of non-financial assets**

An impairment loss is recognised for the amount by which the asset's carrying amount exceeds its recoverable amount. Recoverable amount is the higher of an asset's fair value less costs to sell and value in use. For the purposes of assessing impairment, assets are grouped at the lowest levels for which there are separately identifiable cash inflows that are largely independent of the cash inflows from other assets or groups of assets (cash-generating units). Non-financial assets that suffer an impairment are tested for possible reversal of the impairment whenever events or changes in circumstances indicate that the impairment may have reversed.

An impairment exists when the carrying value of an asset exceeds its estimated recoverable amount. The asset is then written down to its recoverable amount.

### **(w) Business combination**

Business combinations occur where an acquirer obtains control over one or more businesses. A business combination is accounted for by applying the acquisition method, unless it is a combination involving entities or businesses under common control. The business combination will be accounted for from the date that control is attained, whereby the fair value of the identifiable assets acquired and liabilities (including contingent liabilities) assumed is recognised (subject to certain limited exemptions).

When measuring the consideration transferred in the business combination, any asset or liability resulting from a contingent consideration arrangement is also included. Subsequent to initial recognition, contingent consideration classified as equity is not remeasured and its subsequent settlement is accounted for within equity. Contingent consideration classified as an asset or liability is remeasured each reporting period to fair value, recognising any change to fair value in profit or loss, unless the change in value can be identified as existing at acquisition date.

All transaction costs incurred in relation to the business combination are expensed to profit or loss.

The acquisition of a business may result in the recognition of goodwill or a gain from a bargain purchase.

For personal use only

## **19 Summary of significant accounting policies (continued)**

### **(x) Changes in ownership interests**

The Group treats transactions with non-controlling interests that do not result in a loss of control as transactions with equity owners of the Group. A change in ownership interest results in an adjustment between the carrying amount of the controlling and non-controlling interests to reflect their relative interests in the subsidiary. Any difference between the amount of the adjustment to non-controlling interests and the consideration paid or received is recognised in a separate reserve within the equity attributable to owners of Rhinomed Limited.

### **(y) Intangible assets**

Intangible assets are initially measured at cost. Following initial recognition, intangible assets are carried at cost less any accumulated amortisation and any accumulated impairment losses. The useful lives of intangible assets are assessed to be either finite or infinite. Intangible assets with finite lives are amortised over the useful life and assessed for impairment whenever there is an indication that the intangible asset may be impaired. The amortisation period and the amortisation method for an intangible asset with a finite useful life is reviewed at least at each financial year end. Changes in the expected useful life or the expected pattern of consumption of future economic benefits embodied in the asset are accounted for by changing the amortisation period or method, as appropriate, which is a change in an accounting estimate. The amortisation expense on intangible assets with finite lives is recognised in profit or loss in the expense category consistent with the function of the intangible asset.

#### *(i) Goodwill*

Goodwill is carried at cost less any accumulated impairment losses. Goodwill is calculated as the excess of the sum of:

- the consideration transferred;
- any non-controlling interest; and
- the acquisition date fair value of any previously held equity interest;

over the acquisition date fair value of net identifiable assets acquired.

The acquisition date fair value of the consideration transferred for a business combination plus the acquisition date fair value of any previously held equity interest shall form the cost of the investment in the separate financial statements.

Fair value uplifts in the value of pre-existing equity holdings are taken to profit or loss. Where changes in the value of such equity holdings had previously been recognised in other comprehensive income, such amounts are recycled to profit or loss.

The amount of goodwill recognised on acquisition of each subsidiary in which the Group holds less than a 100 percent interest will depend on the method adopted in measuring the non-controlling interest. The Group can elect in most circumstances to measure the non-controlling interest in the acquiree either at fair value (full goodwill method) or at the non-controlling interest's proportionate share of the subsidiary's identifiable net assets (proportionate interest method). In such circumstances, the Group determines which method to adopt for each acquisition and this is stated in the respective notes to these financial statements disclosing the business combination.

Under the full goodwill method, the fair value of the non-controlling interests is determined using valuation techniques which make the maximum use of market information where available. Under this method, goodwill attributable to the non-controlling interests is recognised in the consolidated financial statements.

Goodwill on acquisition of subsidiaries is included in intangible assets. Goodwill on acquisition of associates is included in investments in associates.

## **19 Summary of significant accounting policies (continued)**

### **(y) Intangible assets (continued)**

#### *(i) Goodwill (continued)*

Goodwill is tested for impairment annually and is allocated to the Group's cash-generating units or groups of cash-generating units, representing the lowest level at which goodwill is monitored not larger than an operating segment. Gains and losses on the disposal of an entity include the carrying amount of goodwill related to the entity disposed of.

Changes in the ownership interests in a subsidiary are accounted for as equity transactions and do not affect the carrying amounts of goodwill.

#### *(ii) Intellectual property*

Intellectual property acquired as part of a business combination is recognised separately from goodwill. Intellectual property is carried at cost, which is its fair value at the date of acquisition less accumulated amortisation and impairment losses. Intellectual property is amortised over its useful life commencing from the completion of development. The Group will carry its intellectual property at cost whilst it is under development and it is subject to annual impairment testing.

#### *(iii) Patents and trademarks*

Patents and trademarks are recognised at cost of acquisition. Patents and trademarks have a finite life and are carried at cost less any accumulated amortisation and any impairment losses. Patents and trademarks are amortised over their useful lives.

#### *(iv) Research and development*

Expenditure during the research phase of a project is recognised as an expense when incurred. Development costs are capitalised only when technical feasibility studies identify that the project is expected to deliver future economic benefits and these benefits can be measured reliably.

Development costs have a finite life and are amortised on a systematic basis based on the future economic benefits over the useful life of the project.

Gains or losses arising from de-recognition of an intangible asset are measured as the difference between the net disposal proceeds and the carrying amount of the asset and are recognised in profit or loss when the asset is derecognised.

The carrying values of non-financial assets are tested for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable.

### **(z) Trade and other payables**

Trade and other payables are carried at amortised cost and represent liabilities for goods and services provided to the Group prior to the end of the financial year that are unpaid and arise when the Group becomes obliged to make future payments in respect of the purchase of these goods and services.

### **(aa) Employee benefits**

#### *(i) Short-term obligations*

Provision is made for the Group's obligation for short-term employee benefits. Short-term employee benefits are benefits (other than termination benefits) that are expected to be settled wholly before 12 months after the end of the annual reporting period in which the employees render the related service, including wages, and salaries. Short-term employee benefits are measured at the (undiscounted) amounts expected to be paid when the obligation is settled.

The Group's obligations for short-term employee benefits such as wages and salaries are recognised as a part of current trade and other payables in the statement of financial position. The Group's obligations for employees' annual leave and long service leave entitlements are recognised as provisions in the consolidated statement of financial position.

For personal use only

## **19 Summary of significant accounting policies (continued)**

### **(aa) Employee benefits (continued)**

#### *(ii) Retirement benefit obligations*

All employees of the Group receive defined contribution superannuation entitlements, for which the Group pays the fixed superannuation guarantee contribution (currently 9.5 percent of the employee's average ordinary salary) to the employee's superannuation fund of choice. All contributions in respect of employees' defined contribution entitlements are recognised as an expense when they become payable.

The Group's obligation with respect to employees' defined contribution entitlements is limited to its obligation for any unpaid superannuation guarantee contributions at the end of the reporting period. All obligations for unpaid superannuation guarantee contributions are measured at the (undiscounted) amounts expected to be paid when the obligation is settled and are presented as current liabilities in the Group's statement of financial position.

#### *(iii) Share-based payments*

The Group provides benefits to employees (including Directors) of the Group in the form of share-based payment transactions, whereby employees are provided with long-term incentives through the Group's Employee Option Plan.

The cost of these transactions with employees is measured by reference to the fair value at the date at which they are granted. The fair value is determined using a binomial option pricing model, further details of which are given in note 14. The cost of these transactions is recognised, together with a corresponding increase in equity, over the period in which the options vest.

The cumulative expense recognised for equity-settled transactions at each reporting date until vesting dates reflects:

- the extent to which the vesting period has expired, and;
- the number of awards that, in the opinion of the Directors of the Group, will ultimately vest. No expense is recognised for awards that do not ultimately vest and an adjustment to the expense is made for awards that will no longer vest. This opinion is formed based on the best available information at balance date.

The Group's obligations for short-term employee benefits such as wages and salaries are recognised as a part of current trade and other payables in the statement of financial position. The Group's obligations for employees' annual leave and long service leave entitlements are recognised as provisions in the consolidated statement of financial position.

### **(ab) Borrowings**

Borrowings are initially recognised at fair value, net of transaction costs incurred. Borrowings are subsequently measured at amortised cost. Any difference between the proceeds (net of transaction costs) and the redemption amount is recognised in profit or loss over the period of the borrowings using the effective interest method. Fees paid on the establishment of loan facilities are recognised as transaction costs of the loan to the extent that it is probable that some or all of the facility will be drawn down. In this case, the fee is deferred until the draw down occurs. To the extent there is no evidence that it is probable that some or all of the facility will be drawn down, the fee is capitalised as a prepayment for liquidity services and amortised over the period of the facility to which it relates.

Borrowings are removed from the statement of financial position when the obligation specified in the contract is discharged, cancelled or expired. The difference between the carrying amount of a financial liability that has been extinguished or transferred to another party and the consideration paid, including any non-cash assets transferred or liabilities assumed, is recognised in profit or loss as other income or finance costs.

Borrowings are classified as current liabilities unless the Group has an unconditional right to defer settlement of the liability for at least 12 months after the reporting period.

For personal use only

## **19 Summary of significant accounting policies (continued)**

### **(ac) Issued capital**

Ordinary shares are classified as equity. Any transaction costs arising on the issue of ordinary shares are recognised directly in equity as a reduction (net of tax) of the share proceeds received.

### **(ad) Dividends**

Provision is made for the amount of any dividend declared, being appropriately authorised and no longer at the discretion of the Group, on or before the end of the reporting period but not distributed at the end of the reporting period.

### **(ae) Earnings per share**

Basic earnings per share is calculated as net loss attributable to members, adjusted to exclude costs of servicing equity (other than dividends), divided by the weighted average number of ordinary shares, adjusted for any bonus element.

Diluted earnings per share is calculated as net loss attributable to members, adjusted for:

- costs of servicing equity (other than dividends);
- the after tax effect of dividends and interest associated with dilutive potential ordinary shares that have been recognised as expenses;
- other non-discretionary changes in revenues or expenses during the period that would result from the dilution of potential ordinary shares; divided by the weighted average number of ordinary shares and dilutive potential ordinary shares, adjusted for any bonus element.

### **(af) Parent information**

The financial information for the parent entity, Rhinomed Limited, disclosed in note 17 has been prepared on the same basis as these consolidated statements.

### **(ag) Segment reporting**

Operating segments are reported in a manner consistent with the internal reporting provided to the chief operating decision maker. The chief operating decision maker, who is responsible for allocating resources and assessing performance of the operating segments, has been identified as the Board of Rhinomed Limited. For the current and previous reporting periods, the Group operated in one segment, being the identification, acquisition and commercialisation of late stage therapeutic delivery technologies.

### **(ah) Assets (or disposal groups) held for sale and discontinued operations**

Assets (or disposal groups) are classified as held for sale if their carrying amount will be recovered principally through a sale transaction rather than through continuing use and a sale is considered highly probable. They are measured at the lower of their carrying amount and fair value less costs to sell, except for assets such as deferred tax assets, assets arising from employee benefits, financial assets and investment property that are carried at fair value and contractual rights under insurance contracts, which are specifically exempt from this requirement.

An impairment loss is recognised for any initial or subsequent write-down of the asset (or disposal group) to fair value less costs to sell. A gain is recognised for any subsequent increases in fair value less costs to sell of an asset (or disposal group), but not in excess of any cumulative impairment loss previously recognised. A gain or loss not previously recognised by the date of the sale of the asset (or disposal group) is recognised at the date of derecognition.

Assets (including those that are part of a disposal group) are not depreciated or amortised while they are classified as held for sale. Interest and other expenses attributable to the liabilities of a disposal group classified as held for sale continue to be recognised.

For personal use only



## **19 Summary of significant accounting policies (continued)**

### **(ah) Assets (or disposal groups) held for sale and discontinued operations (continued)**

Assets classified as held for sale and the assets of the disposal group classified as held for sale are presented separately from the other assets in the statement of financial position. The liabilities of a disposal group classified as held for sale are presented separately from other liabilities in the statement of financial position.

A discontinued operation is a component of the entity that has been disposed of or is classified as held for sale and that represents a separate major line of business or geographical area of operations, is part of a single co-ordinated plan to dispose of such a line of business or area of operations, or is a subsidiary acquired exclusively with a view to resale. The results of discontinued operations are presented in the consolidated statement of profit or loss and other comprehensive income.

### **(ai) Critical accounting estimates and judgements**

The Directors evaluate estimates and judgements incorporated into the financial statements based on historical knowledge and best available current information. Estimates assume a reasonable expectation of future events and are based on current trends and economic data, obtained both externally and within the group.

#### *(i) Impairment of intangible assets*

In the absence of readily available market prices, the recoverable amount of assets are determined using estimations of the present value of future cash flows using asset-specific discount rates. For patents, licenses and other rights, these estimates are based on various assumptions concerning for example future sales profiles and royalty income, market penetration, milestone achievement dates and production profiles. Refer to note 6 for further details.

#### *(ii) Impairment of receivables*

The decision whether or not to provide for the impairment of a receivable requires a degree of estimation and judgement. The level of provision is assessed by taking into account the ageing of receivables and specific knowledge of the individual debtor's financial position.

#### *(iii) Share-based payments*

The value attributed to share options and remuneration shares issued is an estimate calculated using an appropriate mathematical formula based on an option pricing model. The choice of models and the resultant option value require assumptions to be made in relation to the likelihood and timing of the conversion of the options to shares and the value and volatility of the price of the underlying shares. Refer to note 28 for more details.

For personal use only

**Rhinomed Limited  
Directors' declaration  
30 June 2017**

In the Directors' opinion:

- (a) the financial statements and notes set out on pages 25 to 63 are in accordance with the *Corporations Act 2001*, including:
- (i) complying with Accounting Standards, the *Corporations Regulations 2001* and other mandatory professional reporting requirements, and
  - (ii) giving a true and fair view of the consolidated entity's financial position as at 30 June 2017 and of its performance for the year ended on that date, and
- (b) there are reasonable grounds to believe that the Company will be able to pay its debts as and when they become due and payable.

Note 19(b) confirms that the financial statements also comply with International Financial Reporting Standards as issued by the International Accounting Standards Board.

This declaration is made in accordance with a resolution of Directors.



Michael Johnson  
Director

Melbourne  
28 September 2017

For personal use only

**Independent Auditor's Report  
To the Members of Rhinomed Limited****REPORT ON THE AUDIT OF THE FINANCIAL REPORT****Opinion**

We have audited the financial report of Rhinomed Limited ("the Company") and its controlled entities ("the Group"), which comprises the consolidated statement of financial position as at 30 June 2017, the consolidated statement of comprehensive income, the consolidated statement of changes in equity and the consolidated statement of cash flows for the year then ended, and notes to the financial statements, including a summary of significant accounting policies, and the directors' declaration.

In our opinion, the accompanying financial report of the Group is in accordance with the *Corporations Act 2001*, including:

- a) giving a true and fair view of the Group's financial position as at 30 June 2017 and of its financial performance for the year then ended; and
- b) complying with Australian Accounting Standards and the *Corporations Regulations 2001*.

**Basis for Opinion**

We conducted our audit in accordance with Australian Auditing Standards. Our responsibilities under those standards are further described in the *Auditor's Responsibilities for the Audit of the Financial Report* section of our report. We are independent of the Group in accordance with the auditor independence requirements of the *Corporations Act 2001* and the ethical requirements of the Accounting Professional and Ethical Standards Board's APES 110 *Code of Ethics for Professional Accountants* ("the Code") that are relevant to our audit of the financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

**Material Uncertainty Regarding Going Concern**

We draw attention to Note 19(B)(I) of the financial report, which indicates that the Group incurred a loss of \$4.442 million (2016: loss of \$5.999 million) had a net operating cash outflow of \$2.996 million during the year (2016: outflow of \$6.125 million). These conditions, along with other matters set forth in Note 19(B)(I), indicate that a material uncertainty exists that may cast significant doubt on the Group's ability to continue as a going concern. Our opinion is not modified in respect of this matter.

**HLB Mann Judd (VIC Partnership)**

Level 9, 575 Bourke Street, Melbourne VIC 3000 | GPO Box 2850, Melbourne VIC 3001 | DX 154 Melbourne | Tel: +61 (0)3 9606 3888 | Fax: +61 (0)3 9606 3800

Email: [mailbox@hlbvic.com.au](mailto:mailbox@hlbvic.com.au) | Website: [www.hlbvic.com.au](http://www.hlbvic.com.au)

Liability limited by a scheme approved under Professional Standards Legislation

## Key Audit Matters

Key audit matters are those matters that, in our professional judgement, were of most significance in our audit of the financial report of the current period. These matters were addressed in the context of our audit of the financial report as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters. In addition to the matter described in the *Material Uncertainty Related to Going Concern* section, we have determined the matters described below to be the key audit matters to be communicated in our report.

Key Audit Matter	How our audit addressed the key audit matter
<p><b>Impairment of intangible assets</b> <i>Refer to Note 6A 'Intangible Assets'</i></p> <p>At 30 June 2017, the Group's balance sheet includes goodwill of \$1.565 million, capitalised development costs of \$254 thousand, and intellectual property of \$1.859 million. In line with the entities segment allocation, these are all assigned to the single Cash Generating Unit ("CGU").</p> <p>The assessment of impairment of the Group's intangible assets incorporates significant judgement in respect of factors such as discount rates, future revenue forecasts, and growth in key markets.</p> <p>The Group is exposed to potential impacts of economic uncertainty in Australia and overseas, varied consumer acceptance of the product, regulatory obstacles, cost pressures, and increases in the entities weighted average cost of capital.</p> <p>Whether the Group's value in use and fair value models for impairment included appropriate consideration of such variables, as well as appropriate underlying assumptions, is why impairment of assets is considered a key audit matter.</p>	<p>Our procedures included, but were not limited to:</p> <ul style="list-style-type: none"> <li>• We assessed management's determination of the Group's CGU based on our understanding of the nature of the Group's operations. We also analysed the internal reporting of the Group to assess how earnings streams are monitored and reported.</li> <li>• We evaluated management's process regarding evaluation of the Group's assets to determine any asset impairments.</li> <li>• We tested entity level controls in place, such as the preparation and review of budgets and forecasts. These forecasts take into consideration the impacts of the sector and geographic specific challenges that the Group may face.</li> <li>• We challenged the Group's assumptions and estimates used to determine the recoverable value of its assets, including those relating to forecast revenue, cost, capital expenditure, and discount rates by adjusting for future events and corroborating the key market related assumptions to external data.</li> <li>• We checked the mathematical accuracy of the cash flow models and agreed relevant data to the latest forecasts.</li> <li>• We obtained and read reports prepared by management's expert, including assessing the competence and capability of management's external expert;</li> <li>• We assessed the historical accuracy of forecasting of the Group.</li> <li>• We performed sensitivity analysis over the model by focusing on the impact of changing growth and discount rates.</li> </ul>

For personal use only

## Information Other than the Financial Report and Auditor's Report Thereon

The directors are responsible for the other information. The other information comprises the information included in the Group's Annual Report for the year ended 30 June 2017, but does not include the financial report and our auditor's report thereon.

Our opinion on the financial report does not cover the other information and accordingly we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial report, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial report or our knowledge obtained in the audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

## Responsibilities of the Directors for the Financial Report

The directors of the Company are responsible for the preparation of the financial report that gives a true and fair view in accordance with Australian Accounting Standards and the *Corporations Act 2001* and for such internal control as the directors determine is necessary to enable the preparation of the financial report that gives a true and fair view and is free from material misstatement, whether due to fraud or error.

In preparing the financial report, the directors are responsible for assessing the ability of the Group to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the Group or to cease operations, or have no realistic alternative but to do so.

## Auditor's Responsibilities for the Audit of the Financial Report

Our objectives are to obtain reasonable assurance about whether the financial report as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with Australian Auditing Standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this financial report.

As part of an audit in accordance with the Australian Auditing Standards, we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial report, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Group's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the directors.
- Conclude on the appropriateness of the directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or

conditions that may cast significant doubt on the Group's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial report or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the financial report, including the disclosures, and whether the financial report represents the underlying transactions and events in a manner that achieves fair presentation.

We communicate with the directors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide the directors with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with the directors, we determine those matters that were of most significance in the audit of the financial report of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

## **REPORT ON THE REMUNERATION REPORT**

### **Opinion on the Remuneration Report**

We have audited the Remuneration Report included in pages 10 to 20 of the directors' report for the year ended 30 June 2017.

In our opinion, the Remuneration Report of Rhinomed Limited for the year ended 30 June 2017 complies with section 300A of the *Corporations Act 2001*.

### **Responsibilities**

The directors of the Company are responsible for the preparation and presentation of the Remuneration Report in accordance with section 300A of the *Corporations Act 2001*. Our responsibility is to express an opinion on the Remuneration Report, based on our audit conducted in accordance with Australian Auditing Standards.

A handwritten signature in dark ink that reads 'HLB Mann Judd'.

**HLB Mann Judd**  
**Chartered Accountants**

A handwritten signature in dark ink that appears to read 'Nick Walker'.

**Nick Walker**  
**Partner**

Melbourne  
28 September 2017

For personal use only